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Bupivacaine is an amide-type local anaesthetic, and is popular because of 
its anaesthetic properties - high potency, dense sensory and motor 
blockade, and long duration of action. However bupivacaine is probably 
more cardiotoxic than any other local anaesthetic in use today. The United 
States Food and Drug Administration withdrew approval of 0. 7 5% 
bupivacaine for use in obstetric anaesthesia in 1984, owing to reports of 
cardiac arrest with this concentration. In lower concentrations 
bupivacaine remains useful for regional and local anaesthesia. 
Bupivacaine is similar to lignocaine in its central nervous system toxicity; 
however its tendency for cardiotoxicity would seem greater. 
Bupivacaine toxicity is a major hazard in anaesthesia. When bupivacaine 
toxicity occurs, it is frequently manifest as disturbances of cardiac 
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conduction leading to ventricular fibrillation and 1s particularly 
intractable to all forms of treatment. The mortality, from bupivacaine 
toxicity, is considerable. In a 1985 report to the F.D.A. the manufacturers of 
bupivacaine reported 12 cases of cardiac arrest- 10 of them fatal[3]. Despite 
this, bupivacaine is the most widely used regional anaesthetic drug because 
of its advantages of quality of block and duration of action. There are, 
however, no satisfactory mechanisms for treating . the cardiac disturbances 
that occur in cases of toxicity. Three recent cases experienced by the 
Groote Schuur Group, have suggested that magnesium sulphate may, 
uniquely, reverse bupivacaine toxicity. The first, a paediatric case having 
a caudal anaesthetic block developed ventricular arrhythmia's which 
reversed immediately following a 20mg/kg intravenous dose of magnesium 
sulphate. The second was a case at the Somerset Hospital following an 
epidural block where, again, intractable arrhythmias occurred which 
responded to infusions of magnesium sulphate. A 3rd case occurred in a 
child following a caudal block using bupivacaine. A bizarre ventricular 
arrhythmia was treated initially with magnesium sulphate ( 1 Omg/ kg) with 
a good result. 
A literature search reveals that one previous study[l 1] has analysed the 
interaction between bupivacaine and magnesium. In this study, 
magnesium was administered at the same time as bupivacaine in a canine 
model. Magnesium sulphate was shown to protect against the prolonged QT 
interval and the prolongation of the QRS complex. This study did not 
investigate the potential role of magnesium in treating established 
bupivacaine arrhythmia's. It therefore appears important to investigate 
this potential role for magnesium, as it may offer the first really effective 
form of therapy for what is currently a potentially lethal complication. 
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2. CARDIAC ELECTROGENESIS 
AND ION CHANNELS 
ION CHANNELS IN THE HEART 
ELECTRO PHYSIOLOGICAL CONSIDERATIONS 
2.1 · ION CHANNELS IN THE HEART 
A repetitive, precisely choreographed sequence of currents through 
families of Na+, ea++, K+ and c1- channels is responsible for generating the 
normal sinus rhythm of pacing potentials, and it is the transmission of 
these signals through specialized conduction pathways, and cardiac action 
potentials which trigger the process of "excitation-contraction" coupling. 
The latter series of events depends on a separate set of ion channels and 
results in the release of intracellular ea++ which produces the physical 
interaction between actin artd myosin resulting in contraction. An 
understanding of the different types of channels, how they regulate flow 
of ions across the membrane and how the sequence is arranged, is 
necessary to be able to understand how bupivacaine's cardiac effects are 
mediated. Only then may we begin to speculate as to how any specific 
treatments may work. An advance in our ability to treat toxicity may occur 
by chance. A breakthrough in our ability to treat bupivacaine toxicity may 
help to explain the mechanisms of bupivacaine's toxic effects. 
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The fundamental units of cardiac excitability are ion channels, complex 
glycoproteins embedded in the plasma membrane of cardiac myocytes. 
There are many different types of cardiac ion channels and ion pumps 
which together orchestrate a complex process that results in the cardiac 












Fig. 1. The upper panel illustrates a ventricular myocardial 
cell action potential. The lower panel shows a schematic QRS-
T complex. The figure shows that the upstroke of the action 
potential (phase 0) occurs as sodium and then calcium move 
across the cell membrane from the extracellular to the intra-
cellular compartment. This portion of the action potential ii 
responsible for the QRS complex of the ECG which is re-
corded as the ventricular cells are sequentially depolarised. 
The plateau of the actio~ potential (phase 2) results from the 
balance between the inward movement of calcium ions and 
the outward movement of potassium ions. This portion of 
the action potential is responsible for the ST segment of the 
ECG. The phase of rapid repolarisation (phase 3) occurs as 
potassium! ions'· move across the membrane from the intra-
cellular to 'the extracellular compartment. This portion of the 
action potential is responsible for the T wave of the ECG 
which reflects the sequential rapid repolarisations of th/ven-
tricular cells [from Harper & Genes ( 1988), with permission]. 
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Phase O (Vmax) of the action potential is a sodium dominated current in 
atrial and ventricular myocardium and also in His-Purkinje fibres whereas 
the SA and AV nodes phase O is dominated by calcium currents. The 
cumulative upstrokes of the atrial action potentials are responsible for the 
p waves on the body surface ECG. The cumulative upstrokes of the 
ventricular action potential are responsible for the QRS complex. The 
maximal rate of rise (Vmax) is a major determinant of the conduction 
velocity and duration of the QRS complex on the ECG. Slowing of Vmax by 
sodium channel blockade is therefore reflected as an increase in the QRS 
duration on the body surface ECG. 
The rapid upstroke is followed by phase 1 and this is followed by a 
prolonged period of slow repolarization (phase 2) which results from a 
balance between inward and outward currents. The inward currents are 
predominantly carried by calcium ions and the outwards currents by 
potassium ions. This plateau is reflected on the body surface ECG by the ST 
segment. The phase of rapid repolarization (phase 3) results from the 
enhanced outward movement of intracellular potassium ions across the cell 
membrane. The rapid repolarization phase restores the membrane to its 
resting potential and corresponds to the relative refractory period - this 
time is reflected on the body surface ECG as the T wave. 
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3. BUPIV ACAINE 
3.1 CHEMICAL PROPERTIFS 
3.2 MECHANISMS OF ACTION 
3.1 CHEMICAL PROPERTIES 
Bupivacaine is a member of the amide group of local anaesthetic agents and 
is a structural homologue of mepivacaine. It consists of a lipophilic 
aromatic group linked to a hydrophilic tertiary amine group by linked by 
an intermediate amide chain which is an important determinant of the 
duration of action [117]. Bupivacaine has a pKa of 8.1 at 25° C and this value 
is dose enough to blood pH that significant changes in the ratio of ionized 
to un-ionized drug species have been shown to occur during acid-base 
imbalances [106]. 
Bupivacaine is 96% protein bound and although highly protein bound at 
lower concentrations, the ratio of free to bound drug increases rapidly as 
concentration increases [1]. The 2 proteins involved in binding are alpha-
1-acid glycoprotein (AAG) and albumin [70] Binding to AAG is a high 
affinity-but saturable process. This is important as these two proteins are 
not as abundant in infancy as in childhood and adults. A decrease in 
protein binding of bupivacaine of up to 50% [106] has been reported in the 
foetus and neonate, and may last until 6 months of age. 
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3.2 MECHANISMS OF ACTION 
It is a tertiary base and is administered as bupivacaine hydrochloride [B-
HCL] which is water soluble. After injection the amine base is liberated by 
the relative alkalinity of the tissue. The tissue will therefore contain both 
the ionised [BH+] and the unionised [B] whose relative proportions will 
depend on the pH of the solution and the pKa. The non-ionized base diffuses 
through the nerve sheath, perineuronal tissues and neuronal membrane to 
reach the nerve axoplasm where it partially dissociates again. 
B + H+<->BH 
In the ionized form BH+ it enters the sodium channel from the axoplasm 
and either occludes the channel or results in channel closure. 
Sodium channels exist in activated-open, inactivated-closed, and rested-
closed states during various phases of the action potential. In the resting 
nerve membrane, sodium channels are distributed evenly between the 
rested-closed and inactivated-closed states. By selectively binding to sodium 
channels in inactivated-closed states, local anaesthetic molecules, 
especially bupivacaine stabilize these channels in this configuration and 
prevent their change to rested-closed and activated-open states in response 
to nerve fibre impulses. Sodium channels in the inactivated-closed state are 
not permeable to sodium and thus conduction of nerve impulses in the form 
of propagated action potentials cannot occur. It has been speculated that 
local anaesthetics, including bupivacaine, bind to specific sites located on 
the inner portion of sodium channels, as well as obstructing sodium 
channels near their external openings to maintain these channels in the 
inactivated-closed states. 
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Frequency dependent blockade is frequently seen with local anaesthetics 
including bupivacaine. Sodium channels tend to recover from local 
anaesthetic-induced conduction blockade between action potentials and to 
develop additional conduction blockade each time sodium channels open 
during an action potential(frequency dependent blockade). Therefore local 
anaesthetic molecules can gain access to receptors only when the s_odium 
channels are in the activated-open (lignocaine) or inactivated-closed 
(lignocaine + bupivacaine ) states. For this reason selective blocking of 
nerve fibres may be related to the characteristic frequencies of activity of 
a nerve, as well as to its anatomical properties such as diameter. So a nerve 
that is being repetitively stimulated is more sensitive to blockade than one 
in the resting state. 
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4. CARDIAC EFFECTS OF 
BUPIV ACAINE 
4.1 EVIDENCE IN HUMANS 
4.2 EVIDENCE IN ANIMAlS 
4.1. EVIDENCE IN HUMANS 
Initially bupivacaine was thought to be a safe local anaesthetic agent and 
in 1966 during development trials it was even given intravenously in doses 
of up to 0.75 mg/ kg to volunteers [17]. 
In 1975, Scott [66] performed a study which would probably now be 
considered unethical. Five medically qualified subjects to received 
infusions of bupivacaine, etidocaine and lignocaine to determine the 
features of toxicity. They received bupivacaine and etidocaine at 1 Omg/ min 
by infusion until a total dose of 125mg had been given or either the subject 
or an observer thought that symptoms were too severe. In 2 subjects the 
bupivacaine infusions were terminated at 80 and 105mg after severe 
objective signs of toxicity. The etidocaine group all received the full 125 mg 
dose. The major difference concerned the frequency and severity of 
lightheadedness and muscle twitching. Four of the five bupivacaine 
subjects had symptoms and 2 of them severe enough muscle twitching to 
require termination of the infusion. None of the etidocaine infusion had 
any objective, observer-noted signs of toxicity. Numbness of the tongue 
and circum-oral tissues was observed in all but 1 of the infusions and 
probably reflected the vascularity of these tissues, giving rise to 
sufficiently high concentrations of the drugs at terminal nerve endings to 
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cause numbness in these areas. The peak plasma concentrations were 
similar in the bupivacaine and etidocaine groups despite the mean dose of 
bupivacaine being slightly lower at 112mg compared to 125mg for 
etidocaine. The disappearance of etidocaine from the plasma was 
considerably faster than for bupivacaine. Of note in their discussion is that 
all the signs and symptoms of toxicity were referable to the CNS. They note 
cardiovascular alterations which included an increase in heart rate and 
blood pressure by almost 20 %, and yet failed to see any significance in 
these changes as they observed no ECG changes. Current thinking on the 
cardiac effects of toxic doses of bupivacaine includes the possibility of some 
autonomic nervous system activation and the observed tachycardia and 
hypertension may well have been evidence of this phenomenon. 
Moore et al [63] published a series of 11080 anaesthetics with only 15 
systemic toxic reactions. Unrecognised intravascular injections were 
responsible for 13 of the cases and rapid absorption after intercostal block 
with typical doses in the other two. 
Edde [7] reported a case of cardiac arrest(ventricular fibrillation) associated 
with needle withdrawal after an interscalene brachia! plexus block which 
they attributed to a subarachnoid injection. Following early intubation, 
adrenaline and defibrillation he made a full recovery. The patient had 
multiple problems including chronic renal failure, hypertension, cardiac 
failure and hypocalcaemia. Albright included this case in his editorial[l 7], 
describing 6 patients, in whom he thought that unrecognised intravascular 
injection had most probably occurred. 
Cottrell [16] in one of the early descriptions of the haemodynamic effects of 
bupivacaine pointed out that the commercially prepared preparation of 
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bupivacaine and 1 :200 000 adrenaline may be associated with profound 
cardiovascular changes. Both patients being were invasively monitored 
during thoracic surgery, and both developed cardiac compromise following 
intercostal nerve blocks with bupivacaine at the end of an e>..1:ended period 
of cardiovascular stability[16]. The first case involved the performance of 
an intercostal block using 112 mg bupivacaine( with 1 :200 000 
adrenaline)which resulted in a transient increase in arterial pressure 
followed by sudden profound hypotension which failed to respond to IV 
calcium chloride, ephedrine and sodium bicarbonate. Finally 
noradrenaline infusion was required for 12 hours to maintain an adequate 
perfusion pressure. 
The second case also involved an intercostal block using 75 mg bupivacaine 
in 1:200 000 adrenaline. An arterial bleed was noted at the injection site of 
one of the · intercostal blocks. Immediately following bupivacaine injection 
this patient developed frequent multifocal premature ventricular 
contractions and following an initial surge in blood pressure it 
progressively fell over 20 minutes despite a 50 mg bolus of lignocaine, 
which appeared to halt the premature ventricular contractions. Blood loss 
had been minimal and the blood pressure failed to respond to 3000ml of 
Ringer's lactate and only following a unit of whole blood did the pressure 
increase. Of note was that the post-operative ECG was unchanged from 
baseline. 
Of note is that the one patient ( described by Cottrell ) failed to respond to 
calcium chloride, ephedrine and sodium bicarbonate and only responded to 
a nor-adrenaline infusion. The second patient's ventricular extrasystoles 
responded to intravenous lignocaine although the blood pressure was only 
restored with a transfusion of blood. Cottrell [16] concluded that caution 
should taken with the doses used via the intercostal route, particularly in 
the face of cardiac failure and general anaesthesia. 
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Albright [1 7] during 1979, in an early editorial on bupivacaine toxicity 
· comments on 6 anecdotal cases of sudden cardiovascular collapse associated 
with rapid intravenous injection of bupivacaine and etidocaine. All the 
cases · occurred in operating rooms under the direct supervision of 
anaesthesiologists following negative aspiration tests. Sudden 
cardiovascular collapse(ventricular fibrillation or ventricular tachycardia, 
asystole, or complete heart block with P waves only) occurred almost 
immediately after rapid injection of the local anaesthetic agent, so that 
antecedent hypoxia was probably not an aetiological factor. It would seem 
that only one of these 6 cases resulted in death and that the other cases 
responded to prolonged resuscitation. He concluded that local anaesthetics, 
including bupivacaine may result in almost simultaneous seizures and 
cardiovascular collapse. 
In October of 1983 Albright made a personal presentation to the Food and 
Drug Administration's Anesthetic and Life Support Advisory Committee [93]. 
He reported a series of 49 cases of cardiac events, either cardiac arrest or 
ventricular tachycardia requiring cardioversion. These were all cases 
within a 10 year period in the United States. The majority of these cases 

























The report to the FDA resulted in the withdrawal of 0.75% bupivacaine from 
obstetric use in the United States. Albright's editorial and the attention 
given to his representation to the FDA probably resulted more importantly 
in an increased awareness of the dangers of local anaesthetic toxicity. The 
resultant introduction of test doses(with or without adrenaline), 
fractionated dosing and increased patient monitoring have probably all 
been responsible for increased safety associated with the use of local 
anesthetic agents. 
In a further report in the 1984 Winter/Spring news letter of the Society of 
Obstetric Anesthesia and Perinatology [93], Albright reported 52 deaths 
following bupivacaine, 31 of which were maternal and 5 which were infant 
deaths. Unfortunately this information remains unpublished. 
The British literature initially supported the use of bupivacaine for I. V.R.A 
until some early case reports described CNS toxicity soon after injection 
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despite apparently functional tourniquets (78,116]. When the Committee on 
Safety of Medicines (UK) records were examined in 1981 (78] it was noted 
that between 1963 and 1976 a total of 14 cases of toxicity with bupivacaine 
had been reported. Three cases had reported seizures during epidural 
anaesthesia with bupivacaine and one of these had been fatal. Quite 
possibly this patient may have experienced accompanying cardiac toxicity. 
In 1978 the first case of seizure with I.V.R.A. and bupivacaine was reported. 
In 1979 five cases were reported, four of them during I.V.R.A. [78]. This 
sparked some interest in comparing the efficacy and toxicity of various 
local anaesthetic agents for I.V.R.A. (77,85,92,116]. At the same time the 
Department of Health and Social Security (DHSS) in the United Kingdom had 
been informed of five deaths directly attributable to I.V.R.A.[115]. The 
patients were all healthy and being treated for minor conditions in 
accident and emergency departments. All cases involved bupivacaine and 
separate tourniquets, all procedures were performed without a designated 
anaesthetist. This DHSS report prompted an editorial in the British Medical 
Journal [115] which came out strongly in favour of better training about 
equipment use and the presence of an anaesthetist to supervise the 
anaesthesia. Whilst the same editorial provided good evidence that 
prilocaine was as effective as bupivacaine and the toxicity profile better 
the author failed to recommend that bupivacaine was to be discouraged 
from use in I.V.R.A.[115]. 
Davis [9] describes another successful resuscitation following early 
institution of supportive therapy during awake surgery for epileptic focus 
excision. 
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Mallampati (10] describes a successful resuscitation with early seizure 
termination, intubation and ventilation following presumed intravascular 
injection during brachia! plexus block. 
Hasselstrom et al [ 40] studied 8 human volunteers. He observed the effect of 
producing plasma bupivacaine levels approximating those achieved during 
epidural anaesthesia. Hasselstrom and workers [ 40] found that plasma levels 
around 1.8ug/ ml produced a 10-15% increase in heart rate accompanied by 
a steady and progressive increase in blood pressure( l 0-15 mmHg) and a 
decrease in cardiac output of up to 20 %. They could find no evidence of a 
change in CVP, o>.ygen consumption, plasma cortisol, blood lactate, FFA's or 
blood glucose although there was a small rise in plasma catecholamine 
levels. This they felt indicated that there was probably no major activation 
of the sympathetic nervous system and it was concluded that some of the 
changes were possibly due to some inhibition of cardiac sympathetic nerve 
activity as had been shown with lignocaine previously [ 40] . In addition 
they felt that the poor correlation of total plasma bupivacaine 
concentration with the cardiovascular effects was probably suggestive of 
differences in protein binding, intracellular transport and sensitivity. 
Mazoit et al [70] looked at the pharmacokinetics of bupivacaine in 13 
infants undergoing caudal anaesthesia for hernia repair and measured 
plasma levels and free fraction to determine the kinetics. It was shown that 
following 2.5mg/ kg doses the plasma levels peaked at 10-60 minutes 
following injection and that the peak plasma levels varied enormously 
from 0.55-1.93 ug/ ml. The area under the curve (AUC) also showed wide 
variation with a range of 201-1107 ug/ min/ ml. The free fraction showed a 
negative correlation with age and this was evident until 6 months of age. 
They concluded that the increased free fraction reported previously in 
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neonates was evident and was present until 6 months of age and that 
therefore practitioners should be careful with the doses administered in 
young infants. 
A case was reported [43] of ventricular fibrillation induced by accidental 
flushing of the pericardium with bupivacaine. A single DC shock was 
necessary to cardiovert the patient and he made a good recovery. 
Ved et al [46] described 2 cases of cardiac toxicity following caudal 
anaesthesia in infants. Both cases received standard doses of bupivacaine 
and soon after being turned into the prone position were observed to have 
cardiovascular collapse which was accompanied by ventricular tachycardia 
in both cases, one of which remitted spontaneously and one received 
lmg/ kg lignocaine. Neither case had evidence of analgesia or paralysis, 
suggesting intravenous injection, and both had no sequelae. 
McCloskey and colleagues [6 7] reported three cases of bupivacaine toxicity 
in children following caudal infusion postoperatively. Case one involved a 
3. 98 kg full-term neonate who received a 2.Smg/ kg bolus and 2 further 
boluses of 1.87mg/ kg at 1.5 and 3 hours after initial bolus. Then 2 hours post 
surgery an infusion of 2.Smg/ kg/ hour was commenced and 10 hours later 
a bradycardia and hypotension were noticed and the serum bupivacaine 
concentration at the time was 5.6ug/ ml. Cardiac massage and ventilation 
followed by 1 Oug/kg adrenaline intravenously resulted in ventricular 
tachycardia and this only settled following 3 boluses of lignocaine and 
Smg/ kg phenytoin. The VT recurred 2 hours later and failed to respond to 
bretylium( 4mg/kg) but responded to diazepam(0.25mg/kg) and 
phenytoin(7mg/ kg) given to control accompanying seizures. 
20 
Case 2 was 8 years old and received similar doses of bupivacaine 
intraoperatively and an analgesic infusion of 1.6 7mg/kg/hour of 0.25% 
bupivacaine and 1:200000 adrenaline. 25 hours after infusion commenced 2 
generalized convulsions occurred associated with serum bupivacaine level 
of 6.6ug/1. 
Case 3 was a 4 year old weighing 12 kg who received a 2.5mg/kg bolus and 3 
further boluses of 1.6 7mg/kg followed by an infusion at 1.6 7mg/kg/hour. 
26 hours later the catheter was resited for technical reason and 8 hours 
thereafter seizures commenced associated with serum bupivacaine 
concentrations of 10.2ug/ml. 
Roitman et al [44] reported a case of successful cardiac resuscitation 
following an intercostal nerve block using 100mg bupivacaine in a patient 
receiving digoxin and metoprolol ( a beta-blocker). The patient required a 
surprisingly short period ( 15 min) of CPR and this led to some speculation 
regarding the potential cardioprotective or cardiopriming action of these 
cardiac drugs. de Jong in a letter to Anesthesia and Analgesia [30] felt that 
the reason the outcome was good was that patient was conscious and 
therefore the postulated central action of bupivacaine causing 
cardiotoxicity was allowed to occur at a lower plasma level than if the 
patient were anaesthetised. Hence the appearance of cardiotoxicity before 
seizures. He felt that the literature supports the postulate that CNS toxicity is 
more likely to occur in anaesthetised patients compared to conscious 
patients as under anaesthesia the central cardiac stimulatory effects are 
suppressed and hence higher plasma levels are required to produce cardiac 
toxicity ; therefore CNS toxicity presents first. 
Whereas the reporting authors had postulated that the cardiac glycoside 
and beta blocker combination was an aggravating combination which acted 
by lowering the threshold for cardiac toxicity, (and hence the occurrence 
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of cardiovascular collapse at lower plasma levels allowed a rapid 
resuscitation); de Jong [30], felt that these drugs may be useful in the 
·treatment or prevention of bupivacaine cardiotoxicity. 
Brown et al [38] looked prospectively at 25697 regional anaesthetics in a 
large teaching institution over 7 years specifically analysing the incidence 
of seizures and associated cardiovascular changes. He found that the 
incidence varied depending on the type of block ( caudal> brachia! 
plexus>epidural route), and that even amongst the different approaches to 
the brachia! plexus there was a differing incidence. He found that the 
practitioners' experience of blocks during that period was not associated 
significantly with seizure occurrence. 
Table 2 Overall Seizure Rates During Regional Anaesthesia[38] 
Anaesthetic Total procedures Seizures Seizure/ 1000 
Caudal 1295 9 6.9 
Brachia! Ple>..'US Blocks 7532 15 2.0 
Axillary 6620 8 1.2 
Interscalene 659 5 7.6 
Supraclavicular 253 2 7.9 
Epidural 16870 2 0.1 
Bupivacaine was the local anaesthetic most frequently associated with 
seizures, and in spite of 16 patients developing seizures after bupivacaine 
blocks, none e>..'J)erienced acute cardiovascular collapse [38]. This data may 
be of use in predicting which patients are at risk of cardiac toxicity. One 
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could postulate that the procedures with a high incidence of CNS toxicity 
are likely to have a lower incidence of cardiovascular toxicity, but in 
similar ratios to CNS toxicity. 
Peutrell (68] looked at the bupivacaine levels associated with continuous 
extradural infusions in 8 children aged 3-12 months . They received a mean 
initial dose of 1.2mg/kg and an infusion at a mean rate of 0.38mg/kg/hour. 
The bupivacaine concentrations are represented in Table 3. 
Table 3 Time Course of Peripheral Venous Total Plasma Concentration 
Bupivacaine concentration( ug/ml) 
Patient No. 4h 8h 16 h 24h 32 h . .40 h 
1 0.21 0.36 0.78 1.26 0.81 
2 0.91 
3 0.96 0.96 0.55 0.60 0.79 
4 1.0 0.36 0.51 0.54 0.66 
5 1.0 0.8 0.67 
6 0.89 1.15 0.92 0.83 
7 0.55 0.70 0.79 0.6 0.87 0.36 
8 0.91 1.01 1.11 1.3 2.02 
Patient 8 showed clear evidence of accumulation with time. The authors 
concur with the view that babies less than 6 months of age have increased 
potential for bupivacaine toxicity due to increased free fraction (70]. 
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Seizures have been reported (68] to occur at plasma concentrations of 
bupivacaine as low as 2ug/ml. This work of Peutrell (68] showed that even 
at infusion levels within the limits of current guidelines that infants can 
show accumulation to levels above that shown to be associated with 
seizures. Peutrell (68] also comments on work by Wolf analysing plasma 
concentrations of bupivacaine in 20 children between 2 and 48 months of 
age, which showed that 2 children, weighing 10 and 8.3 kg had 
concentrations of 2.5 and 3.7ug/kg after 24 hours of an epidural 
bupivacaine infusion. No toxic side effects were reported. Larsson and 
colleagues looked at 7 children under 7 months and measured plasma 
bupivacaine concentrations at 6 and 12 hours following an initial dose of 
1.5-1.9mg/ kg bupivacaine with adrenaline. They then infused bupivacaine 
at 0.5-0.83 mg/ kg/ hour without adrenaline and showed an accumulation at 
6-12 hours with a mean concentration of 1.59ug/ ml(range 1.2-2.1) at 6 
hours and 2.06ug/ ml(range 1.53-2.98) at 12 hours. Two children had CNS 
side effects. 
Sullivan and Abbott (47] reported 2 cases of suspected cardiac toxicity 
following accepted doses of intra-articular bupivacaine, one having had a 
fracture into the joint which may have contributed to the rapid absorption. 
Both cases exhibited ventricular tachycardia and the outcome was 
favourable. 
4.1.(1) SUMMARY OF HUMAN EXPERIENCE: 
Cardiac toxicity was an unrecognised problem during the early use of 
bupivacaine and it was not until Albright published his early observations 
that clinicians became aware of the potentially lethal complications of this 
drug. At the same time the British literature had been reporting cases of 
toxicity[78,,92,115]. This prompted a surge in clinical case reports and in 
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animal e:x.'Perimental work in attempts to explain the complication. More 
importantly, it resulted in an increased awareness amongst ordinary 
clinicians, and the incidence of case reports has decreased significantly 
over the 2nd decade following Albright's editorial. 
Mulroy's review of epidural anaesthesia in 1997 [95] summarised the 
incidence of systemic complications with epidural anaesthesia over the 
past 4 decades. The incidence of systemic complications in the 3 series 
between 1955 and 1964 was between 1.1 and 12.0%. Since Albright's editorial 
in 1979 the incidence published has been between 1.0 and 0.01 %. Two large 
studies involving a total of 34309 epidural anaesthesia patients, had 
incidences of systemic reactions (unspecified) of 0.1 and 0.01 %. 
A prospective questionnaire looked at the serious complications related to 
regional anaesthesia during 1996 in France [114]. They had a low response 
rate of 736 from 4927 questionnaires. They asked anaesthetists to document 
problems over a 5 month period during which data was collected from 
103730 regional anaesthestics (40640 spinal, 30413 epidural, 21278 
peripheral blocks and 11229 I.V.R.A block). There were 98 reported 
complications but one had inadequate details [114]. When the remaining 97 
were analysed there were 32 cardiac arrests, 7 of the fatal. Twenty-six of 
the deaths were during spinal anaesthesia and accounted for 6 of the 
deaths, the small doses used in spinal blocks are highly unlikely to account 
for a systemic cardiac effect of local anesthetic agents. Seizures attributable 
to high plasma levels of local anaesthetics occurred in 23 patients but no 
cardiac arrest occurred in this group[l 14]. 
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The authors of these reports express the view that the increased awareness 
and the use of specific techniques such as aspiration and adrenaline-
containing test doses account for the improved safety. 
In conclusion toxicity with bupivacaine remains a serious hazard and the 







Total dose of drug 
Site of injection 
Protein binding [105, 106] 
Early seizure termination 
Oxygenation 
Cardiac failure, has been shown [104] to result in higher 
concentrations of lignocaine during an infusion preceded by a 
loading dose. These results suggest that the clearance of lignocaine, 
which is twice that of bupivacaine[lOS], is limited by the hepatic 
blood flow. This may be compounded by the fact that many of these 
patients have an acidosis which means that the lipophilic portion of 
the molecule decreases. The low cardiac index means that the 
perfusion of many organs will be decreased. These factors can 
initially give high concentrations of local anaesthetic agents in the 
circulation and relatively well perfused organs such as the heart and 
brain may receive excessively large amounts of the drug resulting 
in toxic effects [104]. 
* Acid base status 
As pointed out above it is not only the total concentration of the drug 
that must bt: taken into consideration but also the drug 
concentration in terms of the prevailing acid-base status and how 
that may affect the state of dissociation and the ionised fractions 
[104]. 
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The incidence of toxic manifestations would seem to have decreased over 
the last three decades. This is possibly as a result of: 
* The use of test doses 
* Attention to equipment 
* Awareness 
Anaesthetic literature and textbooks have highlighted the problems 
relating to bupivacaine cardiotoxicity, and there is no doubt that 
current anaesthetists appreciate the toxicity of bupivacaine far more 
than their earlier counterparts. 
* Dedicated anaesthesia staff 
The change in practice as recommended in the UK [115] led to a 
dedicated anaesthetist being present during 1.V.R.A. In addition 
anaesthetic departments had to accept more responsibility for 
training casualty officers, on an ongoing basis about the equipment, 
drugs and resuscitation of patients during I. V.R.A. 
There are no well proven treatments for established toxicity apart from 
early seizure termination and oxygenation. This is owing to the poor 
understanding of the mechanism of the cardiac effects. Furthermore 
researches are restricted to animal studies in their attempts to elucidate the 
mechanisms of toxicity and any potential treatments. Data derived from 
various species of laboratory animals may not be applicable to humans, as 
there would seem to be significant differences in the electrophysiology of 
mouse I rat hearts and those of higher mammals [personal communication, 
J Vandenberg, Dept of Biochemistry, Cambridge University, UK]. 
Vandenberg and others believe that the more prominent early 
repolarization in mouse action potentials(AP's) gives rise to a shorter AP 
duration. The transient calcium current occurs during the AP in humans as 
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opposed to following the AP in small rodents, so that the relationship of 
channel opening to the depolarization is not comparable. Similarly the 
· "switching off'' of the sodium current is more due to "closing of an 
activation gate rather than opening of an inactivation gate". These 
concerns need to be considered when interpreting many of the studies on 
bupivacaine including the present study which was conducted in rats .. 
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4.2. EVIDENCE IN ANIMALS 
The severe cardiac effects associated with bupivacaine largely preclude 
human experimentation. Animals have become the accepted source of 
intact and isolated tissue models for the toxic effects of bupivacaine. In this 
section the toxicity profile, as determined in animal models, is reviewed. 
The following section summarises work done in animals to establish the 
mechanisms of bupivacaine's toxic effects. Finally previously explored 
treatment options are discussed. 
4.2.( 1) TOXICITY PROFILE 
Local anaesthetic drugs vary not only in the · doses required to produce 
toxicity but also in the response of different systems to toxic serum levels, 
as well as in the final mechanism of death. Nancarrow et al [79] studied the 
toxic dose and the mechanism of death in sheep. They subjected chronically 
invasively monitored animals to increasing doses of one of the local 
anaesthetic drugs on successive days until death occurred. The mean fatal 
dose of lignocaine was 30.8mg(_ +s.8mg), for bupivacaine was 3.7(- +1.1mg) 
and that for ropivacaine was 7.3mg (- +1.0mg). Thus the ratio of toxic doses 
was approximately 9: 1 :2. In four out of four lignocaine treated animals, 
respiratory depression with bradycardia and hypotension without 
arrhythmias was the cause of death. Three out of four bupivacaine treated 
animals died after the sudden onset of ventricular tachycardia/ fibrillation 
without hypoxia or acidosis. The fourth bupivacaine animal died in a 
similar manner to the lignocaine animals. Three out of the five animals 
given ropivacaine died in a similar manner to animals in the lignocaine 
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group. However unlike the lignocaine treated group these animals also had 
periods of ventricular arrhythmia's. The remaining two ropivacaine sheep 
died of sudden onset ventricular arrhythmia's / fibrillation. 
Tanz et al [1] showed in isolated guinea pig hearts that 3ug/ml bupivacaine 
produced rhythm disturbances in 50% of preparations. The commonest 
arrhythmia's were 2: 1 heart block, bigemini, pulsus alternans and 
trigemini[l]. These authors [1] also showed a significant decline (to 58% by 
90 minutes) in coronary blood flow in isolated vertebrate hearts exposed to 
3ug/ml of bupivacaine. This correlated with a concomitant decrease in 
contractility and Mvo2 consumption. Isolated pig coronary arteries were 
then exposed to bupivacaine and no coronary constriction could be 
demonstrated. It was therefore concluded that the decrease in coronary 
flow was a consequence of the decrease in metabolic needs[l]. 
Bupivacaine has been associated with other arrhythmias including 
widening of the QRS, increased QRS amplitude and an increased number of 
ectopic beats with a predominance of nodal and ventricular arrhythmias 
[1]. 
Studies on guinea pig hearts seemed to indicate that the relative 
cardiotoxicity between lignocaine and bupivacaine [24] was the same as 
their anaesthetic potency ratio. Nath et al[24] used an intact pig model with 
selective cannulation of the left anterior descending coronary artery to 
compare the action of bupivacaine and lignocaine on cardiac contractile 
force and electrophysiology without interference from the CNS. This 
required the intracoronary administration of the drug and excluded any 
effect on the SA and AV nodes. Using sequential increments of either drug 
they were able to demonstrate the ECG changes of the drugs without CNS 
interference and the bupivacaine animals demonstrated the well described 
changes of QRS widening, QT interval increasing and a change in T-wave 
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polarity and electrical axis. Predictably PR interval was unchanged as the 
drug was delivered to the ventricle only and therefore nodal and high His-
bundle changes were not expected. Both lignocaine and bupivacaine 
produced dose dependent cardiodepression peaking 5 sec after the 
injection. Following the high doses a 30 % average reduction in left 
ventricular contraction (LV dP/dT) and an increase in left ventricular end 
diastolic pressure (LVEDP) of 25% was recorded. The cardiodepressant ratio 
was comparable with the local anaesthetic ratio of 1:4. These results were in 
accordance with other studies showing that the primary causes of death 
from bupivacaine cardiotoxicity are conduction disturbances and 
ventricular fibrillation. The 4mg/kg dose of bupivacaine resulted in 
ventricular fibrillation induced cardiac arrest in all 7 animals receiving 
this dose. The equivalent lignocaine dose of 16mg/kg resulted in no deaths 
but this group of survivors were then exposed to 32 and 64 mg/kg 
lignocaine and 3 of the 5 animals receiving 64 mg/kg died in a similar 
manner to those receiving bupivacaine. 
Kotelko et al [13] injected sheep (tracheotomised, with oxygen 
supplementation and thiopentone seizure termination) with equivalent 
(low dose) obstetric epidural doses of bupivacaine and (double dose) high 
dose, and found that all sheep had nodal or ventricular arrhythmia's. The 
most common ECG abnormality was widening of the QRS complex which 
occurred in all animals regardless of the dose. Other abnormalities included 
supraventricular tachycardia, atrioventricular conduction blocks, 
ventricular tachycardia, multiform premature ventricular contractions 
and ST-T wave changes. ST-T wave depression of 2mm from baseline control 
was considered significant. 
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Rosen et al [S] studied sheep receiving bupivacaine under conditions of 
mild hypoxia and moderate hypercarbia. They found that in sheep, 
receiving a low dose (2.1.mg/ kg) of bupivacaine, that 3 out of 6 animals had 
significant haemodynamic changes and that all sheep had evidence of 
serious ECG changes or arrhythmias. One of the animals died. Animals 
given high dose ( 4.2 mg/kg) also had evidence of significant ECG changes 
and despite vigorous resuscitative attempts became hypotensive and died. 
The most common ECG abnormality was wide QRS-bradycardia, occurring in 
most animals regardless of the dose. Two-thirds of the animals given high 
dose bupivacaine had electr_omechanical dissociation (EMD) and refractory 
asystole. 
de Jong [8] studied cats and found that adequately ventilated and oxygenated 
cats were able to survive twice the convulsant dose of bupivacaine, and if 
hypotension was corrected with ephedrine they could survive 3 times the 
convulsant dose. They found that regular nodal and ventricular 
arrhythmias appeared with bupivacaine and etidocaine but not with 
lignocaine. They also found that the QRS complex began to widen and 
increase in amplitude before the dose of bupivacaine given reached 1 
mg/ kg. All bupivacaine treated animals had arrhythmias by the time that 
seizures started. 
Nancarrow et al [79] studied sheep receiving a toxic dose. They compared 
the mechanism of death employing different local anaesthetics and found 
that although bupivacaine is approximately four times more potent that 
lignocaine as a local anaesthetic, it is approximately nine times more lethal. 
Therefore the margin of safety would be smaller after the inadvertent 
intravenous injection of bupivacaine than an equipotent dose of 
lignocaine. This they felt was not based on a greater uptake, of bupivacaine 
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into the brain and myocardium, as they could demonstrate no significant 
difference in brain and blood concentrations following lethal doses. 
Bupivacaine [79] may be arrhythmogenic in the absence of marked 
hypoxia, respiratory or metabolic acidosis, hyperkalaemia or hypotension. 
However there is work showing that acidosis, hyperkalaemia and other 
local conditions may decrease the threshold for bupivacaine toxicity, and 
Nancarrow's work showing that acidosis failed to increase tissue 
concentrations in myocardium and brain suggests that the effect of acidosis 
may not be mediated through greater brain or myocardial uptake. This 
work [79] showed that the percentage of each agent isolated from the brain 
and myocardium after fatal doses was similar for all three agents studied. 
They conclude that their results support the proposition that the observed 
differences in cardiotoxicity between agents are due to qualitative 
differences with respect to their effects on cardiac electrophysiology, and 
not because of disproportionate uptakes into the myocardium 
Concern about the poor outcome from cardiopulmonary resuscitation 
following cardiac arrest with bupivacaine has led to work on potentially 
safer long acting local anaesthetic agents. The related amino-amide local 
anaesthetic drug ropivacaine is thought to possess a safer CNS-cardiac 
toxicity ratio and is prepared as a pure S-enantiomer. Feldman et al [32] 
established the convulsant dose of bupivacaine and ropivacaine in beagle 
dogs and then in a blinded fashion gave twice that dose and managed any 
cardiac changes aggressively with closed cardiac massage, adrenaline, 
bretylium, atropine and direct current cardioversion. The intravenous 
administration of 4.3mg/ kg of bupivacaine and 4. 9mg/ kg of ropivacaine 
(the convulsive doses) resulted in overt seizure activity in all animals. All 
animals survived without cardiovascular support. Within 30 seconds of 
administration of the convulsive dose and in conjunction with overt seizure 
33 
activity, a 54% increase in heart rate occurred in both groups. After 
abolition of seizures, heart rates in both groups returned to pre-drug 
· values and remained there. The convulsive dose of either drug caused no 
significant changes in the PR or QT interval on the ECG. The QRS duration 
was increased approximately 30 % in both groups between 1 and 3 minutes 
after local anaesthetic administration. Significant increases in systolic, 
diastolic and mean arterial pressure occurred in both groups for the first 
minute following drug injection and concurrent with seizure activity. 
Following twice the convulsant dose the results were different. Twice the 
convulsant dose of ropivacaine resulted in seizures which were treated 
with intravenous thiamylal after which the dogs were intubated and 
ventilated with oxygen enriched air. 83% required no further 
resuscitation, one dog received adrenaline and bretylium and a second had 
a brief period of ventricular ectopy which settled spontaneously. All 
ropivacaine treated dogs survived. In the bupivacaine group all dogs had 
successful control of seizures with thiamylal and respiratory support was 
instituted. 6 7% of dogs required no further treatment; however 2 dogs died 
despite resuscitative measures including multiple doses of adrenaline, 
manual chest compressions, atropine, bretylium and DC cardioversion. They 
concluded that in their study designed to mimic the clinical occurrence of 
bupivacaine cardiotoxicity that the results were in accordance with those 
of Chadwick [51] where 20% of cats were unresuscitatable. In this study 33% 
of the dogs receiving bupivacaine died despite resuscitation attempts. 
Chadwick's study [51] involved 20 cats which were anaesthetised, paralysed 
with pancuronium and ventilated to avoid the possible effect of acidosis, 
hypoxia and hypercarbia. They used EEG seizure activity as a CNS endpoint 
and a mean arterial pressure (MAP) of lOmmHg as cardiovascular endpoint. 
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They then infused bupivacaine at a rate of 4mg/kg/min and lignocaine at 
16mg/kg/min and recorded the times to each endpoint. 
They found that the onset of electrical seizure activity was virtually the 
same in both groups. Despite the earlier onset of electrocardiographic 
changes in the bupivacaine group, mean arterial pressure was greater and 
remained so for longer than in the lignocaine group. They established that 
the CV /CNS toxicity ratio was 4.0 with lignocaine and 4.8 with bupivacaine. 
Despite very high lignocaine plasma levels all animals were resuscitatable, 
while 2 of the bupivacaine group were not resuscitatable although this was 
not statistically significant. 
The use of pancuronium in this study may have influenced the results in 
the light of more recent evidence implicating the central activation of the 
sympathetic nervous system in bupivacaine cardiotoxicity. The value 
attached to the CV /CNS toxicity ratios needs to be interpreted in the light of 
the assumptions made at the design stage when they equated an infusion 
rate of 4mg/kg and 16mg/kg per minute to be equal for bupivacaine and 
lignocaine respectively. Presumably this based on the commonly quoted 
potency equivalents of 0.5% bupivacaine being equipotent with 2% 
lignocaine. 
The echocardiographic evaluation of bupivacaine cardiotoxicity in dogs 
was studied by Coyle [36] . The temporal relationship with the ECG changes 
was studied in 9 pentobarbital anaesthetised dogs. They found that the 
overall sequence of electrocardiographic changes was that initial systolic 
dysfunction was followed by right ventricular dilatation. This right 
ventricular dilatation was so profound that it was associated with massive 
septa! shift into the left ventricle. These significant changes of systolic 
function occurred before the ECG changes of serious arrhythmias. 
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de La Coussaye et al [25] undertook an elegant study to test the hypothesis 
that bupivacaine facilitates the occurrence of ventricular reentrant 
dysrhythmias. They used isolated rabbit hearts in a standard Langendorff 
perfusion system. An endocardial cryotechnique was employed to destroy 
most of the myocardium except the epicardium, which was then studied, 
using high resolution ventricular epicardial mapping to determine 
whether reentrant phenomenon were taking place. There were 5 intact 
rabbit hearts maintained as controls. These intact hearts produced no 
spontaneous dysrhythmias during exposure to 0.2, 0.5, and 1.0 ug/ ml 
bupivacaine. However during exposure to 5ug/ml bupivacaine, ventricular 
tachycardia occurred in three of five hearts. By programmed electrical 
stimulation using up to three premature beats and maximum pacing rate, 
ventricular fibrillation was induced in all hearts during the control ( no 
bupivacaine ). During administration of 0.2ug/ ml bupivacaine, ventricular 
fibrillation was induced in 3 of 5 hearts using the same protocol. In the 
remaining 2 hearts only sustained monomorphic ventricular tachycardia 
and non sustained monomorphic ventricular tachycardia could be induced. 
During administration of 0.5 ug/ ml, the spectrum of dysrhythmias induced 
by programmed electrical stimulation was completely different. In 1 of 5 
hearts ventricular fibrillation was induced, whilst the other 4 hearts could 
only be induced into sustained monomorphic ventricular tachycardias. 
After the endocardium was frozen, all measurements were performed 
during ventricular pacing because no spontaneous atrioventricular 
conduction was present. No spontaneous ventricular dysrhythmias were 
observed. One preparation exhibited sustained monomorphic ventricular 
tachycardia after rapid pacing during control perfusion. However in 3 of 6 
preparations, sustained monomorphic ventricular tachycardia was induced 
at 0.2ug/ ml bupivacaine. Epicardial mapping demonstrated that all these 
ventricular tachycardias were based on reentry. At bupivacaine 
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concentrations greater than 0.2ug/ml no ventricular arrhythmia was 
induced. Analysis of the complete sequence of activation during initiation 
of ventricular tachycardias showed a marked slowing of conduction, arcs of 
conduction block and reentry around these arcs of conduction block. This 
was considered the first evidence that ventricular reentrant tachycardia 
could be induced by bupivacaine. No dysrhythmias could be induced at 
concentrations greater than 0.2 ug/ml bupivacaine in the frozen heart. 
This may be explained by the inability to pace the heart rapidly at greater 
concentrations of bupivacaine. This bupivacaine inexcitability had also 
been previously described by Moller et al [6] and Lacombe et al [75] in 
rabbit hearts. 
Mets et al [21] observed the cumulative effects of bupivacaine and 
lignocaine in rats. They studied 71 rats and allowed them to breathe 
spontaneously following intraperitoneal pentobarbitone. They then 
received infusions of lignocaine (2%), bupivacaine (0.5%) or both (1 % and 
0.25% respectively). A control group received saline intravenously. Once 
the infusions were begun the haemodynamic and respiratory variables 
were monitored until arrest of either occurred. The times to respiratory and 
cardiac arrest were similar in the lignocaine, bupivacaine and mi> .. 1:ure 
groups. Interestingly they noted that in all animals respiratory arrest 
occurred before cardiovascular collapse. They used the cumulative doses of 
lignocaine and bupivacaine administered separately to determine a 
, 
lignocaine to bupivacaine ratio; this was found to be 3.36. They could 
therefore determine lignocaine-equivalent doses and use these to interpret 
the mixture. They concluded that the mixture of lignocaine/bupivacaine 
was no more toxic than the individual compounds. however their was no 
difference in the lignocaine-equivalent doses of the 3 groups and it can 
therefore be concluded that bupivacaine and lignocaine are additively 
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toxic. Interestingly they only observed one seizure and attributed this low 
incidence to the use of pentobarbital. 
In a study in isolated dog hearts observing the effect of differing 
concentrations of lignocaine and bupivacaine on electrophysiology, 
Wheeler et al [73] studied the drugs' effects on the intact conduction system. 
They found that both lignocaine and bupivacaine reduced the spontaneous 
rate of isolated dog ventricles, lignocaine exhibited a cessation of right 
atrial electrical and mechanical activity more so than bupivacaine, and 
noradrenaline (0.2microgram/ml) was successful in reversing these 
changes. Using micro electrodes to impale the sinus node region they were 
able to track electrical activity in that area and the results are recorded in 
the following table: [From 73, page 205] 
Table 4 Transitional Cell Action Potential Characteristics 
Transitional Cell Action Potential Characteristics 
Phuc 4 Depolariution 
Takeoff 
~le MDP Potcnt i31 Overshoot MRD APD,o Early Late 
Solution N, N, (min-') (mV) (mV) (mV) (V /,ec) (m,cc) (V / sec) (V/ scc) 
Control 7 22 86:: 15 -62:: 7 -54 ± 5 4.4 :: 4.2 11.5 ± 11.0 129 ± 13 .045 ± .026 .0056 ± .0049 
Lidocaine 
(25-35 µg / ml) 3 7 67 ± 2• -61 ± 6 -53 ± 6 2.0 ± 5.2 4.1 ± 2.9 143±17* .026 ± .008 .0058 ± .0014 
Bupivacaine 
(1.75-2.5 µg / ml) 3 5 86 ± 14 -60 ± 3 -54 ± 2 1.2 ± 8.0 2.0 ± 1.2* 143 ± 7* .036 ± .013 .0084 ± .0078 
Significance P < .05 NS NS NS P = .05 P < .05 NS NS 
= not significant. Figures stated as mean ± standard deviation . Nh = number of 
hearts; N; = number of impalements (one AP per impalement); MOP 
= maximum diastolic potential; MRD = maximum rate of depolariza-
tion; APDw = action potential duration at 50% repolarization; NS 
Significance indicates differences between groups in the columns; 
*denotes a significant difference from control. 
Significant changes were observed in maximum rate of depolarization 
during bupivacaine exposure ( control =11.5 ± 11.0 V / sec, bupivacaine =2.0 ± 
1.2 V/sec) . 
When loss of atrial mechanical activity · occurred it was often in the 
presence of sino-atrial activity but in the absence of conduction ( and no 
action potentials) through surrounding "transitional tissues". They termed 
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this "sinus exit block". This sinus exit block was reversible by the 
administration of noradrenaline and may reflect noradrenaline's 
augmentation of the slow inward current, a well known action of beta-
adrenergic agonists [73]. 
When they analysed the action potential in the interventricular septum a 
small change in the peak amplitude of the action potential spike was found, 
with no change in the plateau height or resting potential, but bupivacaine 
increased the action potential duration, although not in a dose dependent 
manner. 
Wheeler and co-workers' results [73] correlated with previous work 
showing · a concentration dependent decrease in indices of contractility. 
Detailed study of atrioventricular conduction in the presence of 
bupivacaine showed that atrial activity conveyed to the AV node was 
conducted to the septum but did not produce excitation of the atrium. 
However "bizarre" localized blocks and conduction patterns were 
demonstrated within the AV node and these were described as being 
conditions which predispose to re-entrant arrhythmias. They were even 
able to observe premature septal beats which arose from the AV node, with 
re-entry being the likely mechanism of the extra beats. 
Interesting observations [73] were made on the effects of bupivacaine on 
action potentials (AP) in the different areas of automaticity, conduction and 
contraction, and it was concluded that this may shed some light on the area 
of the heart specifically influenced by bupivacaine. They showed that 
bupivacaine was 20 times more potent than lignocaine in depressing AP 
properties in atrial cells. In septal cells the AP changes were more 
variable, although the depression of V max was more pronounced with 
bupivacaine. Septal cells also showed an action potential lengthening with 
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bupivacaine. Increased duration of ventricular muscle . action potential 
occurred with bupivacaine and this also occurs with drugs such as 
· quinidine, which like bupivacaine also predisposes to Torsade de Pointes. 
Despite these increases in AP duration, some isolated Purkinje Fibres 
exhibited decreased action potential duration as has been shown with 
· lignocaine. This differing effect on the action potential of Purkinje fibres 
and ventricular muscle may be associated with Torsade de Pointes and 
ventricular fibrillation. 
Arlock [111] studied the action of lignocaine, bupivacaine, and ropivacaine 
on guinea pig papillary muscle sodium channels. He demonstrated a 
depression of the plateau of the action potential in paced myocardium by all 
the drugs. In higher doses the action potential overshoot was decreased and 
the action potential shortened in paced preparations. Different stimulation 
protocols were used to assess use-dependent block, evaluate recovery from 
use-dependent block, and to evaluate the relative contribution of 
activation-dependent and inactivation-dependent block. They demonstrated 
recovery intervals, following 19 conditioning impulses, of 0.186s for 
lignocaine, 1.4s for ropivacaine and 2.1 s for bupivacaine. Analysing these 
data they estimated that the percent of drug-blocked channels at the end of 
the 19th beat was 88% for the bupivacaine compared to 48% and 75% for the 
lignocaine and ropivacaine respectively. This confirms that bupivacaine 
acts on the sodium channels in a use-dependent manner in depressing 
Ymax of the action potential. 
The second part of the study analysed the effect of different stimulation 
rates on Vmax· In the presence of bupivacaine the steady state level of 
V max decreased progressively as the stimulation rate increased from 0.05 to 
3.3 Hz. This confirms the rate dependent nature of block of the sodium 
channels by bupivacaine [111]. In addition it was confirmed that block 
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increased with increasing duration of depolarisation. This is in accordance 
with other work showing that the sodium channels remain in the 
inactivated state and hence more susceptible to bupivacaine when the 
action potential is prolonged. During the final part of the experiment 
preparations were paced with fast trains, of stimuli, with an exceptionally 
short inter-stimulus interval and a very short action potential plateau, 
which demonstrated very little difference between bupivacaine and 
ropivacaine. In addition the onset was slower than with lignocaine. This is 
compatible with the work of Hondeghem, Katzung and others [76,111,3] 
suggesting that lignocaine has higher affinity for activated channels; 
while bupivacaine and ropivacaine seem to bind preferentially to 
inactivated channels. Despite the lack of difference in action potential 
measurements they demonstrated a significant decrease in contractility in 
the bupivacaine preparations. The mechanisms are unclear (111] but a 
reduction in calcium influx due to calcium channel blockade, reduction of 
calcium influx due to shortening of the action potential blockade, 
inhibition of calcium efflux from the sarcoplasmic reticulum, or a 
reduction of intracellular calcium due to reduced intracellular sodium 
activity and inhibition of the sodium-calcium exchange mechanism are 
possible explanations. 
Pitkanen (110] studied the effects of 3 different local anaesthetics on 
inotropy and chronotropy in isolated beating and perfused rabbit hearts. 
Whilst the model could be flawed in that stability was defined as the 
achievement of 3 consecutive readings within 20% of each other, it is still 
worthwhile considering as some of the work does agree with the findings 
of other investigations. Nine concentrations of local anaesthetics were 
studied 6, 20 and 40 micrograms/ ml of lignocaine, and 1, 6 and 13 
micrograms/ ml each of bupivacaine and ropivacaine. During drug 
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exposure a significant slowing in spontaneous heart rate was demonstrated, 
even at low concentrations in the case of bupivacaine. This is contrary to 
previous studies in intact animals, where there is often an early increase 
in blood pressure and heart rate [32,73] and also contrary to our experience 
with infusions of bupivacaine. A human study looking for evidence of 
autonomic activation [ 40] similarly showed an early tachycardia .and I 
postulate that this is evidence of central nervous system involvement in 
intact animals. Thus there may be considerable evidence supporting 
central nervous system involvement in intact humans and animals. 
Pitkanens group [110] produced a 62 % depression of left ventricular 
systolic pressure with the 6ug/ml bupivacaine which was significantly 
different to that produced by an equal concentration of ropivacaine. 
However this isolated heart model excludes possible CNS mediated 
cardiovascular effects of bupivacaine. The following are the results 
obtained in the 13ug/ ml groups: 




2 cases of AV block 2 "almost complete" A-V block 
2 cases nodal/idioventricular rhythm 4 severe ventricular tachycardia 
with AV dissociation with 2 or more foci 
1 ventricular ectopy interrupted by 
beats seemingly preceded by p-wave 
1 animal had no ECG changes 
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Their conclusion, in agreement with the literature, was that a majority of 
the ventricular arrhythmias seen with bupivacaine are re-entrant in 
nature. 
Nath and co-workers [93] performed randomised cross-over experiments in 
pigs anaesthetised with pentobarbitone. They administered lignocaine or 
bupivacaine into isolated anterior descending coronary arteries in a trial 
designed to eliminate any CNS mediated cardiovascular influences. There 
was· a dose-dependent depression of the left ventricle in the same ratio as 
the anaesthetic potency of the two drugs. However comparable 
prolongation of the QRS interval was obtained at a ratio of 1:16. It was 
therefore concluded that bupivacaine was 4 times as potent as lignocaine in 
depressing myocardial contractility, and 16 times as potent when 
considering electrophysiological toxicity [93].Therefore bupivacaine may 
have a 4 times higher electrophysiological effect than myocardial 
depressant effect. 
The "modulated receptor hypothesis" has been used to describe the 
interaction of bupivacaine with sodium channels. According to this 
hypothesis blockade of sodium channels results from interaction of drugs 
with a specific receptor site associated with the sodium channel. Drug 
affinity for this site is dependent upon the state of the channel, i.e. the rate 
constants describing the affinity and dissociation of the drug from the 
receptors are different for each channel state and for different drugs [3]. 
Bupivacaine is similar to lignocaine in that it has a high affinity for 
inactivated channels, but unlike lignocaine it has relatively low affinity 
for open channels [3]. Furthermore bupivacaine may also differ in the 
manner of its interaction with the rested channels. The channel block 
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cannot be reduced markedly by hyperpolarising the membrane, which 
suggests that bupivacaine may slowly or incompletely dissociate from the 
rested channels. The higher potency of bupivacaine over lignocaine at 
physiological heart rates results from both a higher affinity for sodium 
channels as well as a qualitative difference in its kinetics of interaction 
with cardiac sodium channels. The estimated dissociation constant for 
bupivacaine and inactivated sodium channels is 0.9uM(0.3ug/ml) whilst a 
conservative estimate for lignocaine is 10uM(2.3ug/ml) [3] . 
Llgnocaine blocks both open and inactivated sodium channels very rapidly 
and recovery at diastolic potentials is very rapid. Thus lignocaine may be 
considered to block sodium channels in a "fast-in-fast-out" manner. The 
kinetics of block onset and recovery for bupivacaine are different. 
Recovery from block at diastolic potentials is slow whilst development of 
block is slow at low concentrations but fairly rapid at higher 
concentrations. Thus bupivacaine blocks sodium channels in a "slow-in-
slow-out" manner (at low concentrations) and in a "fast-in-slow-out" 
manner (at concentrations >0.2ug/ ml). Because recovery from block is 
always slow the block accumulates even at very low heart rates. 
These differences make bupivacaine much more potent in depressing V max 
in ventricular muscle. Depression of Ymax will result in slowed conduction 
of cardiac action potentials. In an intact heart this can result in prolonged 
P-R intervals and a widened QRS complex. Slowed conduction also can result 
in unidirectional block and re-entry, which in turn can result in the 
production of unifocal or multifocal ventricular ectopics and ventricular 
tachycardias [3]. The proven ability [3] of bupivacaine in concentrations 
above 1 ug/ ml to shorten the action potential duration may explain changes 
in the S-T interval. 
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Symanski and Genes [22], in a review of the effect of drugs on the 
electrophysiology of the heart, comment on the effects of decreasing the 
velocity of Ymax· The rate of maximal rise of the action potential upstroke 
(phase 0) is a major determinant of conduction velocity and duration of the 
QRS complex on the body surface ECG. When the sodium current is 
completely inhibited, the calcium current may still be activated and be of 
sufficient degree to initiate an action potential, but Ymax and conduction 
will be much slowed [22] In general the class I anti-arrhythmic drugs cause 
sodium channel blockade and thereby reduce the Ymax of the action 
potential upstroke, slow impulse conduction, and prolong the QRS complex 
on the body surface ECG. It is difficult to correlate what seems to be 
happening to AP's in individual cardiac cells (nodal, conducting and 
contractile myocardial) and the body surface ECG. The effect of an isolated 
sodium channel blockade on an individual myocyte would be to decrease 
V max, the degree of depolarization and shorten the action potential 
duration. However many drugs, such as class I anti-arrhythmic agents can 
both decrease Ymax and then shorten, lengthen or leave the AP plateau 
duration unchanged. These problems are compounded by the evidence that 
different areas of the myocardium may be affected in a different manner 
by the same drug. Thus attempts to use body surface ECG to interpret the 
effects of drugs affecting the electrophysiology at individual cell level is 
not only difficult, but possibly highly inaccurate. 
Clarkson et al [3] studied isolated guinea pig hearts looking at the onset and 
offset of bupivacaine's cardiac effects and their relationship to stimulation 
rate and diastolic membrane potential. They recognised that the Ymax they 
were measuring in phase O of the action potential was not necessarily an 
exact measure of sodium ion flow but that it had been validated for this 
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purpose [3]. In the presence of bupivacaine 1 ug/ml, Ymax after a long 
period of rest was no different from control. Upon application of a train of 
· beats Ymax declined with each successive action potential until in steady-
state conditions a new Ymax value was reached in about 10 beats. The steady 
state depression was strongly dependent on the number of times that the 
channels were used per unit of time. When bupivacaine was compared with 
lignocaine whilst looking at the rate dependency it was found [3] that 
lignocaine was far more sensitive to changes in heart rate through the 
physiological range. This difference indicates that their potency ratios may 
not be identical at different heart rates. A further technique was used to 
determine when sodium channels were being blocked by each drug, and 
association and dissociation constants were derived for the individual 
drugs; in particular, this could be related accurately to different stages of 
the action potential. Bupivacaine was found to have a high affinity for the 
channel in an "inactivated -closed" state whereas lignocaine had high 
affinities for the "open" and "closed - inactivated" states. It was concluded 
that bupivacaine like lignocaine has depressant effects on the cardiac 
sodium channels that are both "time" and "voltage" dependent. The 
blockade of sodium channels increases as stimulation rate is increased or 
the membrane potential becomes more depolarized. 
For lignocaine, recovery of block was very rapid [3] and occurred during 
diastole so that accumulation only occurs at faster than physiological heart 
rates. The recovery characteristics of bupivacaine are different in that the 
dissociation constant is low at diastolic potentials and the drug therefore 
accumulates even at slow heart rates. These differences make bupivacaine 
much more potent at depressing V max in ventricular muscle at physiologic 
heart rates. 
The cardiac depressant effects of bupivacaine can be attenuated by 
reducing the heart rate, prevention of diastolic depolarization and 
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shortening of the action potential duration. Therefore 
in heart rate such as can be brought about by 
large changes 
abolishing a 
tachycardia could reduce the depressant action of bupivacaine 
on cardiac conduction and thus be beneficial in reducing its 
cardiac toxicity [3]. In addition even a small amount of diastolic 
depolarization would be expected to greatly increase the depressant effect 
of bupivacaine on conduction. Thus conditions known to depolarize the 
cardiac cell membrane( eg. hyperkalaemia, severe hypoxia) are expected to 
increase bupivacaine's depressive effects. Manipulations that shorten 
the duration of the plateau may be beneficial in treating 
bupivacaine toxicity, while conditions that lengthen the action 
potential duration may be expected to worsen toxicity. 
Unfortunately we know of no drug that markedly shortens the 
action potential and is not itself toxic[3] 
Interestingly no correlation could be demonstrated between heart rate and 
predisposition to dysrhythmias. No study has specifically investigated this 
effect in the intact animal. The investigators also expressed concern that 
about the use of hexamethonium, was a general ganglion blocker. They 
could not exclude it from exerting a protective effect, possibly by from 
blocking some pathway in the parasympathetic nervous system [31] . 
Lynch [4] studied various mechanisms which might account for the cardiac 
effects of bupivacaine, compared and contrasted with another lipid soluble 
drug (etidocaine) and a water soluble drug (lignocaine) and found that the 
effects of 1.lSug/ml and 2.88ug/ml bupivacaine was very similar to the 
equivalent concentrations of etidocaine [4]. A dose- and frequency-
dependent depression of contractility was observed which correlated with 
previous work by Courtney [15] and Clarkson and Hondeghem [3]. 
Llgnocaine also caused contractile depression which was more profound at 
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the low frequency range studied; 9.3 7ug/ml lignocaine caused a pattern of 
depression that was similar to that of a tenfold lower concentration of the 
more lipid soluble drugs [4]. With regard to action potential duration 
lignocaine caused a significant decrease at all frequencies up to 2 Hz. 
Bupivacaine and etidocaine were shown to have a similar effect but the 
reduction was not uniformly significant at all frequencies[ 4]. It was 
concluded that there was a reverse frequency dependent depression of 
myocardial contractility. These effects contrasted sharply with the local 
anaesthetic effect on the rate of depolarization of the fast action potential, 
which is used as a measure of sodium ion influx through sodium channels 
[4]. 
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4.2.( 1.1) SUMMARY OF TOXICITY PROFILE 
1. BUPIVACAINE vs LIGNOCAINE 
Doses 
The cardiac effects of bupivacaine begin to be seen at plasma levels 
of 2-4ug/ml [1] and increase progressively with increasing 
concentration. The equivalent changes are only seen at lignocaine 
concentrations of 20:-30ug/ml. These levels of .bupivacaine can be 
reached during caudal [68, 70] and epidural anaesthesia and 
analgesia. Several studies have suggested that the negative 
electrophysiological and inotropic effects are not equal for 
bupivacaine and lignocaine [51,73]. They suggest that bupivacaine 
has electro- physiological effects which outweighs the negative 
inotropic effects. One study [24] demonstrated that the ratio of 
depression of contractility between the bupivacaine and lignocaine 
was 4: 1, which is the same as their anaesthetic potency ratio. 
However the electrophysiologic toxicity ratio was 16:1, indicating the 
profound effects of bupivacaine on electrophysiological conduction 
[24]. 
Mechanisms 
Several studies [21,32,48,79] analysing the mechanisms of death have 
indicated that respiratory failure occurs before severe cardiac 
manifestations. Nancarrow's study [79] seemed to indicate that 
lignocaine resulted primarily in respiratory failure whereas 
mortality due to ropivacaine and bupivacaine in sheep has a 
combination of respiratory and cardiac causes. 
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2. THE CARDIOVASCUIAR EFFECTS OF BUPIVACAINE 
Inotropy 
Both in-vitro [1, 4, 72, 87, 93] and in-vivo [20, 24, 40, 54, 87, 93] studies 
have shown that bupivacaine has profound negative effects on 
contractility that would seem to be independent of any 
electrophysiological ( of specialised conduction tissue ) effect as it 
remains demonstrable in isolated of myocardium and myocytes. 
Chronotropy 
Isolated hearts [73, 110,41] demonstrate a simple dose-response curve 
when bupivacaine concentration is plotted against decreasing heart 
rate. However intact animals [14, 42, 53, 32, 35, 54] and human studies 
[40] seem to indicate a bi-phasic response to increasing 
concentrations of bupivacaine. This is quite possibly the postulated 
central stimulatory action of bupivacaine is absent in the denervated 
isolated hearts and that only its direct action on the cardiac 
pacemakers and conducting tissue is present in this situation. Some 
support for this postulate is the attenuating effect, on bupivacaine 
induced arrhythmia's, seen by Bernards [53] when animals were 
primed with benzodiazepines, which are known to suppress the 
output of the sympathetic nervous system. 
Electrophysiology 
Depression of cardiac conduction appears to be one of the main 
mechanisms of the cardiac effects of bupivacaine. This is largely 
dependent on blockade of the cardiac sodium channel and is 
dependent both on use and the state of the sodium channel. Blockade 
of the sodium channels develops during the upstroke and plateau of 
the action potential and dissipates during the diastolic interval 
so 
between beats. Hence the effect of bupivacaine is both state- ( of the 
channel) and time-dependent (111]. 
It seems that the severe ventricular arrhythmias following large 
doses are the result of reentrant phenomena (11, 25, 26, 73, 88, 112]. 
However many different dysrhythmias have been described 
including increased PR intervals [3,24], broad QRS complexes 
[3,5,8,20,24,26,35,42,47,51] , bradycardia [5,26,30,35,42,49,51,67,73,102], 
bigemini[l,8], trigemini[l], heart block [1,5,12,17,20,30,35,42,45,51], 
pulsus altemans (1,12], nodal beats [2,8], ventricular ectopic beats 
[l,6,8,12,16,42], idioventricular rhythm [8,11,35,91], bundle branch 
blocks [8], ventricular tachycardia [9,10,ll,12,17,20,21,25,32,46,47, 
56,91], prolonged QT interval[l 1,24], Torsade de Pointes[73], 
ventricular fibrillation [1,7,17,24,25,32,43,56,90], electro- mechanical 
dissociation (5] and asystole [5,17,42,51] 
Echocardiography 
An echocardiographic study (36] of the effects of bupivacaine in 
dogs at concentrations less than those required to produce ECG 
changes of toxicity, demonstrated systolic dysfunction followed by 
acute right ventricular dilatation with shift of the septum into the 
left ventricle. 
There is no equivalent study in humans or large primates and 
therefore difficult to interpret. 
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4.2.(2) POSTULATED MECHANISMS OF TOXICITY 
4.2.(2.1) ROLE OF SODIUM CHANNELS 
The focal anaesthetic effect of bupivacaine is mediated by its action on 
sodium channels and a large component of the cardiac toxicity is similarly 
mediated by sodium channel blockade. The major consequence is a slowing 
of V max of phase O of the cardiac action potential. The cardiac effects are 
predominantly in the specialised conducting system of the His-Purkinje 
system and then in atrial and ventricular muscle as these areas rely on 
sodium channels for early and rapid depolarization. Calcium channels are 
able to play a role in a slower depolarization, in the His-Purkinje system 
and the atrial and ventricular myocardium if sodium channels are 
completely blocked. This is in contrast to the sino-atrial and atrio-
ventricular nodes which rely on calcium channels for their phase 0 
depolarization. One of the possible effects of Vmax depression is a slowing 
of depolarization which can be reflected as QRS complex prolongation on 
body surface ECG recordings. 
Hyponatraemia has the potential to decrease the transmembrane sodium 
gradient and therefore possibly potentiate the effect of fast sodium channel 
blockade. Work by Bertrix and co-workers [61] studied the effect of altering 
the sodium concentration - they demonstrated that dog hearts in a 
hyponatraemic environment were able to be induced to show the features 
of bupivacaine toxicity at much lower plasma levels. In addition the 
production of hypernatraemia was shown to reverse some of the cardiotoxic 
changes induced by bupivacaine. Profound hyponatraemia (serum sodium 
100-110) on its own was shown to produce abnormalities similar to those 
produced by moderate hyponatraemia and bupivacaine. 
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4.2.(2.2) ROLE OF CALCIUM CHANNELS 
Calcium has been implicated in the cardiac effects seen with bupivacaine. 
Calcium is important in the action potential conduction in the atrio-
ventricular pathway (the SA and AV nodes in particular). Tanz et al [1] 
exposed isolated vertebrate hearts to additional calcium and could show no 
reversal of bupivacaine's cardiac toxicity. Calcium influx initiates and 
controls the force of contraction in the process of excitation-contraction 
coupling, therefore the determination of whether bupivacaine affects the 
slow inward current is essential to our understanding of the mechanism of 
the cardiac toxicity of local anaesthetics 
Various calcium channel antagonists (27, 87] have been studied in 
association with bupivacaine cardiotoxicity, probably as a result of French 
work by Bedjam and de la Coussaye (123] suggesting that slow calcium 
dependent channels may be responsible for a component of bupivacaine's 
cardiotoxicity. 
Coyle and Sperelakis (64] looked at the ongoing controversy as to whether 
bupivacaine has any action on the calcium slow inward current channels 
[64] .. They studied 12 isolated guinea pig hearts perfused in Tyrodes 
solution. They elevated the K+ concentration to 26mM which raised the 
resting membrane potential to -46mV and inactivated the fast Na+ 
channels. Slow-rising action potentials(AP) were induced with 
isoprotenerol added to the perfusate. Low concentrations of lignocaine or 
bupivacaine did not affect the Vmax of the slow action potentials (AP's). 
Pharmacological concentrations of bupivacaine depressed Vmax by 50% 
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whereas lignocaine in equivalent concentrations had no effect. 
Bupivacaine also caused a significant depolarization of the resting potential 
to -39mV. Washout of lignocaine was rapid and isoprotenerol excitability 
was restored in 3 minutes whereas the bupivacaine washout was 
significantly longer. The bupivacaine concentration necessary to produce 
a Vmax depression of 50% for the slow action potentials (AP's) was s_imilar 
to that required to depress the fast(Na+) channel Vmax by a similar amount. 
This data suggests that bupivacaine does inhibit the slow inward calcium 
current and that the concentration required to produce a 50% decrease in 
Ymax of the slow action potentials in this study is similar to those shown to 
produce the same degree of suppression of Vmax in fast action potentials as 
demonstrated by Clarkson and Hondeghem [3] 
The phase O of the cardiac action potential in both the SA node and the AV 
node is largely calcium dependent rather than sodium channel dependent 
as in the His fibres, ventricular conducting tissue and cardiac myocytes. De 
La Coussaye et al [ 41] studied isolated frog atria to look at the effects of 
increasing concentrations of bupivacaine, and showed a contributory 
effect of calcium channel inhibition. They used the double sucrose gap 
technique. This involves placing a short segment of isolated fibres in a 
bath where a small segment in the centre is isolated by 2 streams of iso-
osmotic sucrose solution, thereby creating an artificial node of Ranvier. 
The central pool between the 2 sucrose streams can be perfused with 
physiological fluid or with test solution. The inside potential of the test area 
is patch-clamped and stimulating voltage can be applied and current flow 
across the membrane can be measured. They used 3xl o-7 M tetrotoxin 
which inhibits the fast inward sodium current [41]. Bupivacaine was added 
to the central test solution at varying concentrations and its effect 
measured. They showed that bupivacaine inhibited the slow-inward 
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current in a concentration dependent fashion. This moderate calcium 
inhibitory effect might explain sinus bradycardia and the slowing of AV 
node conduction observed in anaesthetised dogs following bupivacaine 
infusion. Bupivacaine depressed not only the amplitude but also the 
kinetics of the slow-inward current. The time to reach peak current is 
increased and this allows for increased time for calcium to enter the cells. 
This is counterbalanced to some extent by a decrease in the slow inward 
current amplitude. De La Coussaye feels that this does not e:x.'])lain a 
significant role for calcium and that other factors such as inhibition of 
energy metabolism may be implicated in bupivacaine's ability to decrease 
contractility. 
Despite concerns about the accuracy of using frogs [41] to represent effects 
of bupivacaine in humans the authors felt that their results possibly 
explain the sinus bradycardia and slowing of AV node conduction induced 
by bupivacaine. 
Hyman et al [27] looked at the effect of Nimodipine in 84 rats and 
pretreated 2 groups with 200 and 500 ug/ kg of nimodipine respectively and 
had 2 groups of placebo controlled dogs. They found that the 200ug/kg 
nimodipine pretreatment protects against fatal cardiotoxicity of LDso and 
LD90 bupivacaine although SOOug/kg did not. 
Other work [87] has suggested that the calcium antagonists may potentiate 
bupivacaine's effect on the heart. Recent work by Herzig [87] looked at the 
interaction between various calcium antagonists and bupivacaine, and 
tried to clarify which of the calcium channel antagonists would increase 
the negative inotropy of bupivacaine. In addition they compared the action 
of one calcium channel antagonist (nitrendipine) against various local 
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anaesthetic agents to see if any of the local anaesthetics were particularly 
sensitive to the effects of calcium antagonists. 
The first part of the experiment used isolated guinea pig atria suspended in 
Tyrodes solution. The influence of the calcium antagonists on inotropy 
were recorded using concentration response-curves. They evaluated the 
increase in potency by determining the half-inhibitory concentration 
(ECS()) of bupivacaine for each preparation. They showed an increase in 
negative inotropic potency for bupivacaine in the presence of the 
dihydropyrodine derivatives (felodipine, nifedipine, nitrendipine), 
whereas the amphiphilic calcium antagonists led to a smaller change. The 
degree of potentiation of the negative inotropic effect, as caused by 
nitrendipine, differed between the various local anaesthetics, bupivacaine 
and ropivacaine being affected to a greater extent. 
The second part of the experiment consisted of isolated guinea pig hearts 
suspended in Tyrodes solution with 10% gelatin to help prevent myocardial 
oedema (by maintaining some oncotic pressure). Strain and pressure 
gauges were placed in the cardiac chambers and the surrounding blood 
vessels to record changes in pressures and contractility with time. The 
same technique using dose-response curves was used with differing 
concentrations of the local anaesthetics, with and without the presence of a 
low concentration of nifedipine. The effects of bupivacaine on cardiac 
inotropy, and hence cardiac function, were enhanced in the presence of 
nifedipine. The effects of bupivacaine on cardiac rhythm remained 
unchanged. 
Arlock's work [111] demonstrates bupivacaine's attenuation and block of 
automaticity at potentials where the calcium-conductance is high. This may 
indicate that bupivacaine is affecting the transmembrane calcium current. 
The decreased inotropic effect of bupivacaine, independent of its sodium 
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channel effect, may be due to depression of the transmembrane calcium 
current which is responsible for triggering the contractile apparatus. 
4.2.(2.3) ROLE OF POTASSIUM CHANNELS 
Agents that alter the duration of the plateau phase of the cardiac action 
potential may affect the cardiotoxicity of bupivacaine, because bupivacaine 
induced block of cardiac sodium channels develops mostly during the 
action potential plateau when sodium channels are inactivated. Cardiac 
action potential duration is principally controlled by potassium currents 
flowing through several different voltage-dependent potassium channels. 
If the action potential were prolonged due to potassium channel block, this 
might contribute an additional mechanism for local anaesthetic 
cardiotoxicity because of the increased number of open or inactivated 
sodium channels. 
Avery [118] found in well ventilated and oxygenated dogs that mild 
hyperkalaemia produced cardiotoxicity at a significantly lower dose than in 
the normokalaemic state. 
Courtney [98] studied frog hearts to see if bupivacaine had a blocking effect 
on potassium channels and found that it resulted in a significant blockade 
of the Ik (delayed rectifier potassium current) and Iki (inward rectifier 
potassium current) potassium channels at concentrations which produce 
the well described sodium channel block. Potassium channel block may 
therefore account for part of bupivacaine's reported cardiotoxicity. 
Following work by Clarkson and Hondegmens [3] which showed that 
bupivacaine preferentially bound to the inactivated sodium channels [62] 
other researchers realized that this inactivated state predominates during 
the depolarized plateau phase of the action potential. Thus any condition 
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increasing the time that sodium channels spend in the inactivated state (by 
prolonging the action potential duration) might be expected to enhance the 
·blockage of sodium channels. The duration of the cardiac action potential is 
controlled by currents flowing through a variety of voltage dependent 
potassium channels. These include Ito (transient outward potassium 
channel}, lk (delayed rectifier potassium current) and lki (inward rectifier 
potassium current). Agents which inhibit these currents would be expected 
to increase the duration of the action potential. The studies by Courtney [98] 
and others [62] had aiready reported that bupivacaine was a potent blocker 
of the delayed rectifier potassium current. Castle [62] therefore studied the 
various potassium channels in isolated rat ventricular myocytes using a 
patch-clamp technique. He was able to show that bupivacaine is a potent 
inhibitor of Ito in rat ventricular myocytes. Reports prior to Castle's study 
showed conflicting results concerning bupivacaine's effect on lki and this 
study [62] seemed to confirm that bupivacaine has no effect, even at 
millimolar concentrations, on lki . The studies looking at bupivacaine's 
effect on potassium channels are still rather conflicting. Bupivacaine has 
been shown to increase the action potential duration in frog and canine 
atrial wall muscle and also in canine ventricular septal wall. However the 
action potential duration has been shown to be decreased by bupivacaine 
[62] in canine and rabbit Purkinje fibres. It is possible that there may be 
regional differences in bupivacaine's effect on action potential duration. 
This may result in areas differing in excitability which in turn could 
precipitate re-entrant arrhythmias. So whilst there is no doubt that 
bupivacaine's inhibition of fast sodium channels accounts for the majority 
of its cardiotoxicity, one can not exclude that blockage of potassium 
channels - by prolonging the time sodium channels spend in the 
inactivated state - may potentiate the effects on sodium channels. 
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Bohan et al [45] set out to test the hypothesis that ATP- sensitive potassium 
channel openers could attenuate the bupivacaine induced atrioventricular 
block. They studied isolated and perfused guinea pig hearts and infused 
bupivacaine at two concentrations to produce first degree AV block ( 4ug or 
l.15mg/ml) and second degree heart block (15-20uM or 4.31-5.71ug/ ml) 
respectively. During a stable AV block they administered the potassium 
channel openers (pinacidil and bimikalim). In the presence of 
bupivacaine, pinacidil and bimikalim both attenuated the atrioventricular 
(AV) block induced by bupivacaine by approximately 20 %. The beneficial 
effect of bimikalim was reversed by glibenclamide which is a specific 
blocker of ATP-dependent potassium channels. This seems to support the 
mechanism of the other 2 drugs as being through the K channel. In 
addition the 2nd degree AV block induced by higher doses of bupivacaine 
was converted to 1st degree block by the either pinacidil or bimikalim. This 
work strongly suggests that the AV blocking effect of bupivacaine can be 
partly treated with K channel openers which have the effect of 
accelerating cardiac repolarization. 
Recent modeling of potassium channels in proarrhythmia by Starmer [88] 
found that the cardiac vulnerable period during which stimulation results 
in unidirectional block was prolonged by actions that slowed conduction 
( especially secondary to sodium channel block) of an excitation wave front. 
Thus class 1 agents inherently amplify the probability of initiating reentry 
secondary to unsuppressed premature excitation. In a general sense, 
sodium and potassium currents are complimentary: one depolarizes and the 
other repolarizes. With sodium channel blockade the cellular 
antiarrhythmic property ( prolongation of recovery of excitability) leads 
to a multicellular proarrhythmic property (prolongation of the vulnerable 
period) that destabilises bidirectional wave front formation. Similarly with 
59 
potassium channel blockade, the cellular antiarrhythmic property derived 
from prolongation of the action potential duration [prolonged 
refractoriness] might translate to a multicellular proarrhythmic property 
by prolonging the wavelength (AP duration . velocity) and destabilising 
some other aspect of propagation [88]. Recognising that there may be 
several different modes of initiation of Torsade de Pointes they . used 
computer modeling in the setting of reduced potassium currents. They 
ignored the mechanistic basis for reentrant initiation and hypothesized 
that for some situations the "initiating" and "maintenance" processes are 
distinct and can be explored separately. Recent work by their group had 
shown that potassium channel blockade by quinidine reduced the 
vulnerable period during which reentrant arrhythmias could be 
generated. The reentrant wave front has been observed to be a spiral wave 
rotating around a small core region or it can drift in response to local 
inhomogeneities in the medium. Theoretical studies have shown that the 
properties of the medium can influence the tip of the spiral waveform and 
that shifts in the spiral tip are reflected in the ECG. If the spiral tip rotates 
around a single point then a reentrant cycle will follow the same path and 
be reflected as a monomorphic ECG pattern. Conversely, if the tip rotates 
around a non-stationary region then the reentrant pathways differ and are 
reflected as a polymorphic ECG pattern. 
In this work they looked at polymorphic ECG's in a uniform medium when 
the action potential was prolonged. Action potential duration (APD) 
prolongation was achieved either by reducing the magnitude of the 
generalised potassium conductance, mimicking either channel block or 
hypokalaemia, although similar results could have been obtained by any 
intervention which prolongs the action potential duration. The conclusions 
from this modeling suggest that non-sustained tachycardias and 
ventricular fibrillation seen with long QT syndrome(leading to Torsade de 
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Pointes) and hypokalaemia, or in the presence of potassium channel block 
are compatible with a reentrant process in the setting of diminished 
repolarizing currents [88]. 
In summary potassium channels are involved and may play a role in 
prolonging individual action potentials. This is supported by the action of 
specific potassium channel openers which reverse the effect that 
bupivacaine has on prolonging the action potential plateau. Prolongation 
of the action potential allows the sodium channels to remain in the closed-
inactivated state for longer allowing preferential binding of bupivacaine. 
Action potential lengthening also is thought to predispose to reentrant 
arrhythmias and magnesium may shorten the action potential duration and 
therefore help in reversing bupivacaine's effect. 
4.2.(2.4) ROLE OF AUTONOMIC NERVOUS SYSTEM 
Early in the use of amide local anesthetics it was realised that lignocaine 
stimulated the heart through a central mechanism with a resultant 
increase in cardiac output and mean arterial pressure [103]. 
The autonomic nervous system has recently been implicated in the 
cardiotoxicity of bupivacaine and research has become focused in this 
area. Bernards and Artru [31] looked in anaesthetised rabbits and found that 
intracerebroventricular administration of small doses of bupivacaine 
induced hypertension and cardiac arrhythmias. Moreover, the 
intracerebroventricular administration of midazolam, known to potentiate 
the activity of gamma-amino-butyric-acid(GABA)-ergic neurones that 
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inhibit the activity of outflow neurones of the autonomic nervous system, 
suppressed bupivacaine induced hypertension and arrhythmias. 
In one of the earliest papers implicating the sympathetic nervous system 
in bupivacaine cardiotoxicity Bernards [53] looked at the effect of 
midazolam and diazepam premedication on the CNS and CVS toxicity of 
bupivacaine. Two previous studies had provided inconclusive evidence of 
the role of benzodiazepines and they therefore looked at 3 groups (n=lO) of 
awake swine, one group receiving saline, one diazepam 0.15mg/kg and 
another midazolam 0.06mg/kg as premedication. All animals were 
invasively monitored and aggressively resuscitated once cardiovascular 
collapse occurred. They found that the control group developed 
dysrhythmias earlier than the diazepam/midazolam groups. Blood pressure 
.and heart rate increased during the first 2 minutes of bupivacaine in the 
control group but not in the benzodiazepine groups. The dose of 
bupivacaine to produce CVS collapse and the plasma levels did not differ 
amongst the groups. Animals receiving the benzodiazepines were less 
likely to experience seizures and the diazepam animals were less 
successfully resuscitated. They postulated that the increase in heart rate 
and blood pressure seen in the control group was on the basis of 
sympathetic activation just as it had been shown to stimulate the amygdala 
to cause seizures. 
De La Coussaye et al [35] looked at the putative cardioprotective effects of 
hexamethonium in the presence of cardiotoxic plasma levels of 
bupivacaine. They attempted to determine the mechanism by which the 
autonomic nervous system may plays a role in bupivacaine cardiotoxicity 
and their model consisted of closed chest, pentobarbital anaesthetised dogs 
in 3 groups- the control group getting bupivacaine alone, the second 
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pretreated with 0.2mg/kg atropine and the 3rd pretreated with intravenous 
hexamethonium. Animals in the hexamethonium group were also paced via 
the right atrium to obtain a heart rate similar to the control group. The 
bupivacaine infusion in the control group significantly decreased heart 
rate, lengthened PR, atria-His, His-ventricle and QTc intervals; and QRS 
widening. Atropine pretreatment did not modify cardiac disturbances 
induced by bupivacaine . Hexamethonium pretreatment attenuated QRS 
widening and QTc lengthening but worstened the bradycardia, atria-His 
and PR intervals. They concluded that any drug which maintains better 
cardiac conduction after bupivacaine as demonstrated by 
decreased lengthening of the HY or QRS interval, should also 
prevent the occurrence of ventricular arrhythmias. They argue 
that the deleterious activation of the autonomic nervous system is actually 
activation · of the sympathetic nervous system. They concluded by 
speculating that it may be the increased heart rate which is really the 
cause of the increased toxicity as a result of a use dependent block. 
Bernards et al (31] looked at the intracerebroventricular installation of 
control CSF, Muscimol ( GABA agonist), picrotoxin ( GABA chloride channel 
blocker) and intravenous hexamethonium. These were followed by 
intravenous . bupivacaine infusions. They had previously shown that 
intracerebroventricular administration of midazolam, a drug that enhances 
GABA activity, terminated both the cardiac dysrhythmias and 
hypertension. The increased sympathetic nervous system outflow could 
result from bupivacaine mediated blockade of the GABA-ergic neurons that 
are known to tonically inhibit brainstem sympathetic outflow. Midazolam 
was effective in terminating the dysrhythmias and hypertension possibly 
because it restored the lost GABA -ergic inhibition. However the animal 
models do not yet explain whether the sympathetic nervous system plays a 
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part during accidental intravenous infusion. The plasma levels of 
bupivacaine which produced cardiac dysrhythmias in the muscimol and 
· hexamethonium groups was significantly greater than the control group. 
The plasma c;oncentration of bupivacaine that produced cardiac 
dysrhythmias in the picrotoxin group was no different from control. In all 
groups, cardiac dysrhythmias initially consisted of premature ventricular 
contractions often progressing to multifocal ventricular ectopics, 
bigemini, trigemini or runs of ventricular tachycardia. No animal 
developed ventricular fibrillation. In all animals cardiovascular collapse 
resulted from electromechanical dissociation. Their finding that muscimol 
pretreatment resulted in an increased threshold for bupivacaine induced 
cardiac arrhythmias was consistent with their hypothesis that GABA ergic 
receptors are involved. However they found that picrotoxin pretreatment 
did not decrease the arrhythmia threshold as expected. They speculate that 
it was their conservative dose of picrotoxin that resulted in this lack of 
results. They had arrived at the conservative dose due to an earlier trial 
during which they were able to demonstrate that picrotoxin itself was able 
to induce arrhythmias in sufficient dose. Despite the results showing an 
increased threshold for dysrhythmias in hexamethonium and muscimol 
groups, it did not alter the threshold for cardiovascular collapse. It is 
therefore important to question whether the increased dysrhythmia 
threshold is clinically significant. Death from intravenous bupivacaine 
occurs from either ventricular dysrhythmias or electromechanical 
dissociation ( EMD ) depending on species and individual variability. 
However it is unclear why either should predominate in some species or 
individuals. It would be nice to speculate that in those species and 
individuals who develop ventricular dysrhythmias, that increasing the 
dysrhythmia threshold may also raise the threshold for cardiovascular 
collapse [31]. Interestingly they found no correlation between heart rate 
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and predisposition to dysrhythmias. No study seems to have investigated 
this effect in the intact animal. They also expressed concern that 
hexamethonium was a general ganglion blocker and that therefore they 
could not exclude it from a protective effect from blocking some pathway in 
the parasympathetic nervous system. 
Following evidence that the CNS may be involved in the cardiotoxicity of 
bupivacaine, Richter et al [59] looked, in rats, at the effects of 
arrhythmogenic doses of bupivacaine on the activity of brain medullary 
cells. They were able to demonstrate that intravenous administration of 
bupivacaine results in consistent patterns of cellular inhibition in the 
nucleus tractus solitarius cells. This is in agreement with reports 
describing the direct placement of bupivacaine in the nucleus tractus 
solitarius. Cellular inhibition was often preceded by a period of excitation 
in cortical cells. These changes were felt to be consistent with excitatory 
input to the nucleus tractus solitarius [54]. 
Gerard [54] attempted to help sort out the conflicting literature concerning 
the cardiovascular effects of diazepam and bupivacaine by looking at the 
interaction of the two drugs at therapeutic concentrations rather than the 
toxic plasma levels at which they had both been studied previously. Using 
chronically instrumented mongrel dogs they had 4 groups- group 1 
receiving saline lml/min for 30 minutes; group two receiving diazepam 
0.2mg/kg bolus; group 3 bupivacaine 0.4mg/kg bolus and a bupivacaine 
infusion at 15 microgram/kg/min. Group 4 received the diazepam and 
bupivacaine regimes. 
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SVR = Systemic vascular resistance 
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Down at 5-10 min 
Up at 5-10 min 




LVdP/ dt= Myocardial contractile force 
The primary effect of the diazepam was to induce early vasodilatation, SVR 
decreased at 5 min, with an accompanying increase in HR and CO. Aortic 
pressure and LV dP/ dt (as a measure of myocardial contractile force) 
remained unchanged. The plain bupivacaine group showed a delayed (30 
min) increase in heart rate and LV dP/ dt, without any change in cardiac 
output or aortic pressure. The combined effect of the 2 drugs was a 
decreased SVR and increased heart rate and cardiac output which . occurred 
at 5 minutes. The heart rate was maintained throughout the experiment and 
was not accompanied by any increase in myocardial contractility, unlike 
the bupivacaine alone. 
These results failed to show the dysrhythmic effects seen at toxic doses. 
Bupivacaine alone exerts a sympathomimetic effect which is blunted by 
diazepam. Bupivacaine and diazepam may be a potentially dangerous 
combination as the diazepam could blunt the early warning signs of 
bupivacaine toxicity This may be particularly important during epidural 
block when the sympathomimetic effect may be important in 
counteracting vasodilatation and care should be exercised when using the 
combination in those with impaired cardiac function. 
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Sympathetic tone blockade was investigated by de La Coussaye [52] in dogs. 
They had a control group, a second group received 0.2mg/kg atropine and a 
third group received 0.2mg/kg propanolol. They all received 4mg/kg 
bupivacaine over 10 seconds and various cardiovascular parameters were 
recorded. In all groups the main effect was an impairment of infranodal 
conduction, especially that of the fast inward sodium current. The atropine 
group was no different from control and they concluded that the 
parasympathetic system therefore played no part. The propanolol group 
showed increased susceptibility and this manifest mainly as an increase 
Atria-His conduction time and a greater decrease in mean arterial pressure 
[52]. 
Clonidine has been investigated fairly extensively as an agent for 
attenuating and treating bupivacaine cardiotoxicity. Clonidine is known to 
prolong the duration of sensory and motor block produced by bupivacaine 
and the combination has been used by constant infusion via the epidural 
route for post operative analgesia. de Kock et al [28] looked at 2 groups of 
rats, one placebo and one pre-treated with clonidine 5ug/ kg. The rats were 
anaesthetised with intraperitoneal pentobarbital and tracheotomised and 
ventilated. 15 Minutes following the clonodine/ placebo they received a 
bupivacaine infusion at 2mg/ kg/min. They showed that the dose necessary 
to produce an isoelectric EEG was 58.6 +/- 14.9 mg/kg in the clonidine group 
compared to 22 +/ -6.4 mg/kg in the placebo group(P<0.001) 
In their second experiment they found ventricular dysrhythmias first 
occurring after 10.9 +/- 4.5 min in the clonidine group and 3.2 +/-1.0 min 
in the placebo group(P<0.01) 
The mechanism of this antidysrhythmogenic effect is not elucidated. A 
central site of action is the most probable explanation. The alpha-2 agonists 
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potently inhibit the neuronal firing rate from the locus coeruleus, leading 
to a decrease in sympathetic outflow. This action may decrease the release 
of noradrenaline at the cardiac neuroeffector junctions. If the early signs 
after bupivacaine overdose are caused by increased autonomic nervous 
system outflow, as hypothesised by Bernards and Artu [31], clonidine 
pretreatment may be adequate prevention. 
In addition the clonidine induced bradycardia may be another reason why 
it increases the threshold for cardiotoxicity. Bupivacaine blocks the cardiac 
sodium channels in a " fast in, slow out" fashion subject to use dependence. 
A slower heart rate before bupivacaine overdose allows more time for the 
sodium channel to remain in the closed, configuration, during which time 
the affinity of the bupivacaine for the channel is reduced and bupivacaine 
may move away from its binding site. 
De La Coussaye et al [26] felt that there are two problems in bupivacaine 
cardiotoxicity; firstly the electrophysiologic changes and then the 
haemodynamic disturbance. 
They felt that the main electrophysiologic disturbance induced by 
bupivacaine was a potent inhibition of the fast inward current resulting in 
a slowing of ventricular conduction velocities, which are well known to 
cause reentry phenomenon and hence ventricular arrhythmias. Therefore 
they felt it illogical to try and treat cardiotoxicity with another 
antiarrhythmic drug. They had previously observed that clonidine slightly 
shortens the variables of ventricular conduction velocities represented by 
the His-ventricular (HV) interval and QRS duration in anaesthetised dogs. 
They therefore investigated the hypothesis that clonidine would reverse 
the slowing of ventricular conduction velocities induced by large doses of 
bupivacaine. The haemodynamic disturbances resulted from a bupivacaine 
induced depression of myocardial contractility and therefore contractility 
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need to be improved. Hence they felt the need to add an inotrope to the 
clonidine and selected dobutamine, postulating that adrenaline would be 
more arrhythmogenic. In anaesthetised dogs they looked at five groups all 
of whom received atropine 0.2mg/kg to inhibit vagal responses on the 
sinus and atrioventricular nodes. 
The groups were: 






bupivacaine followed by clonidine(O.Olgm/kg) 
bupivacaine and dobutamine infusion(Sug/kg/min) 
bupivacaine/clonidine and dobutamine 
They found that the bupivacaine group showed significant bradycardia, 
prolonged- the PR(>50%), AH(>30%) and HV(>100%) intervals; and also 
significantly increased the QRS(>100%) duration. The haemodynamic 
effects included a 50 % decrease in LV dP/ dt max and increased 
LVEDP(>50%). 
Comparison with the clonidine/bupivacaine group showed that the dose of 
clonidine (following bupivacaine ) briefly shortens the PR interval, 
decreases QRS duration (3-Smin) and shortens the HV interval (3-Smin). 
Clonidine also significantly enhances bupivacaine induced bradycardia 
The dobutamine following bupivacaine group showed a dobutamine 
increased LVdP/dt max but no change in electrophysiologic parameters or 
LVEDP between groups 4 and 2. The combined treatment significantly 
improved the PR and HV intervals, decreases the QRS duration 
previously impaired by the bupivacaine and increases LV dP/dt. 
Moreover the combination was more effective in bringing about 
these changes than clonidine alone. 
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A further study by the group led by de la Coussaye [34] also looked at the 
possible receptor mechanisms for the cardio-protective action of clonidine 
· in the face of toxic bupivacaine plasma concentrations. They used various 
interventions in intact dogs to block various aspects of the autonomic 
nervous system. They were able to postulate that it was through activation 
of the cardiac vagus nerves, through ganglionic nicotinic receptors that 
clonidine had its positive effect on bupivacaine toxicity. It would seem that 
it was not a direct action via acetylcholine at the nerve terminals but 
possibly_ through an associated neuropeptide such as neuropeptide Y [34]. 
Pitkanen [110] when looking at isolated perfused rabbit hearts found that 
even at low concentrations of bupivacaine there was a sharp decrease in 
spontaneous heart rate. This evidence in denervated organs could be 
confirmation of the CNS effect on toxicity as other work and our own 
e>..rperience in the laboratory is that an initial stimulation of the CVS occurs 
with an increase in mean arterial pressure accompanied by an increase in 
heart rate. 
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4.2.(2.5) ROLE OF LIPID SOLUBILITY AND FREQUENCY 
DEPENDENT BLOCK 
Courtney [15] looked at isolated frog sciatic nerves and measured the height 
of the action potential in response to single stimuli and to repetitive 
stimuli. He found that all the nerves treated with the highly lipid soluble 
agents (bupivacaine, tetracaine, etidocaine) took longer to develop 
conduction block and also to recover from 40 Hz stimuli than the moderate 
lipid solubility agents (procaine, lignocaine, prilocaine, mepivicaine). The 
highly lipid soluble agents required relatively large numbers of impulses 
to reach maximum effect of use in conduction block. They felt that as 
normally sodium channels recover from the inactive state with a time 
constant of 5-1 Omsec, which accounts for the normal refractory period 
following an impulse and that their data, obtained during potassium 
channel blockade, suggested that the frequency dependent conduction 
block is due to an alteration in the process of sodium channel inactivation 
by local anaesthetic drugs. This was despite previous studies [15] showing 
that for the extremely hydrophilic drugs opening of the sodium channel is 
necessary to permit drug to and unbind from the receptor. 
4.2.(2.6) ROLE OF ENANTIOMO-SELECTIVITY 
Bupivacaine is a racemic mixture of 2 enantiomers. It has been long known 
that in some mammals the S( -) enantiomer is of equal or higher potency 
for nerve blocking than the R( +) enantiomer [20] but with less local and 
general toxicity. Thus it is not surprising that the enantiomers have 
differing effects on the heart. Some studies have shown that the S(-) 
enantiomer is less cardiotoxic than the R( +) enantiomer in animal models. 
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However with our current knowledge unable to describe the exact 
mechanism of bupivacaine cardiotoxicity, and particularly that there may 
be multiple sites of action on both sides of the blood brain barrier; it needs 
a concerted research effort to determine the exact role of the 2 
enantiomers. Another significant difference between the 2 enantiomers 
may be the role of differential protein binding and hence differences in 
hepatic clearance of drug [20]. 
Vanhoutte et al [80] looked at the different actions of the 2 enantiomers of 
bupivacaine on cardiac electrophysiology in isolated pieces of guinea-pig 
hearts. They found that the 2 enatiomers had differing effects and 
properties in vitro. R( +) bupivacaine caused a stronger reduction of V max. 
A mean apparent dissociation constant of 16 microM was found for the 
reduction of Ymax at 1 Hz by R(+) bupivacaine versus 39 microM for S(-) 
bupivacaine. Conversely the anaesthetic potency of S(-) bupivacaine seems 
to be larger or equal to that of R( +) bupivacaine. 
At 1 Hz an important amount of use-dependent block was present resulting 
from a block of sodium channels during the action potential and 
incomplete blocking during the diastolic period. R( +) bupivacaine 
unblocked significantly slower than did S(-) bupivacaine at all tested 
membrane potentials. They concluded that the fact that R( +) bupivacaine 
has a greater effect on V max and action potential duration is possibly the 
explanation for the higher in vivo toxicity. Reduction of Ymax slows 
conduction. Too much slowing of conduction and shortening of the action 
potential duration predisposes to reentrant phenomena. This may indicate a 
specific receptor site being involved at the sodium channel rather that a 
non-specific effect on disturbing the membrane. 
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4.2.(2.7) ROLE OF TISSUE UPTAKE 
Concern has been raised about the possible ion trapping of bupivacaine 
within neural and myocardial tissue under hypoxic and acidotic conditions 
such as occur during convulsions and cardiac arrest. This argument has 
been used in attempts to explain the apparent resistance to resuscitative 
efforts following bupivacaine induced cardiac arrest. Nancarrow's work 
[79] found that the percentage of each agent isolated from the brain and 
myocardium after fatal doses was similar for all three agents studied. 
Acidosis failed to increase tissue concentrations in myocardium and brain 
suggests that the . effect of acidosis may not be mediated through greater 
brain or myocardial uptake. They conclude that their results support the 
proposition that the observed differences in cardiotoxicity between agents 
are due to qualitative differences with respect to their effects on cardiac 
electrophysiology, and not because of disproportionate uptakes into the 
myocardium. 
The study by Morishima et al [14], whilst comparing the toxicity of 
lignocaine and bupivacaine in nonpregnant and pregnant sheep, also 
correlated blood and tissue levels in the brain and myocardium in an 
attempt to explain the mechanism of toxicity. Their results showed that 
during a bupivacaine infusion that convulsions were associated with 
hypertension and tachycardia. The dosage given was correlated with the 
plasma level by means of a ratio. Significantly higher dosage and blood 
concentration ratios were noted in the lignocaine group. The tissue/blood 
concentration ratios of bupivacaine were significantly higher than those 
for lignocaine in the lungs and the adrenals. The tissue/blood ratios were 
also greater in the hearts and livers of bupivacaine group but did not reach 
statistical significance. 
73 
At present there is little evidence to support "ion trapping of bupivacaine" 
in cardiac tissue as a contributory factor to its severe cardiac actions. 
4.2.(2.8) ROLE OF DRUG INTERACTIONS 
Several studies looking at the possible role of various ion channels and also 
the studies attemting treatment are indirectly studies examining drug 
interactions. Timour's study [56] looked specifically at the effect of various 
drug interactions, with bupivacaine, on the heart. They found that a 
prolongation of right ve~tricular conduction time was enhanced by 
cibenzoline, disopyramide and propanolol. These changes were not due to 
significant blood pressure changes altering clearance of bupivacaine. The 
increase in conduction disorders with cibenzoline and disopyramide were 
not accompanied by significant changes in the effective refractory period 
and therefore reentrant dysrhythmias were a likely consequence. They 
could show that increasing right ventricular conduction time by more than 
100% resulted in ventricular tachycardia and fibrillation. 
Two other drugs that they studied, clomipramine and verapamil had only 
moderate or no effects when combined with bupivacaine. They felt that the 
potentiation by class 1 c drugs such as cibenzoline could have been 
predicted in view of its ability to block fast sodium channels. Although the 
class 1 a drugs such as disopyramide have less of an effect on fast sodium 
channels it is not surprising that they had a conduction prolonging effect. 
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4.2.(3) POTENTIATING/ ATTENUATING FACTORS 
4.2.(3.1) ROLE OF MAGNESIUM 
The only work looking at the effect of hypermagnesaemia on the 
cardiotoxicity of bupivacaine is that of Solomon et al [11]. They studied 10 
mongrel dogs and induced hypermagnesaemia in one group with a loading 
dose (140mg/kg) followed by an infusion (80mg/kg/hr) to maintain plasma 
Mg++ at 2.42 + 0.18 mmol/1 (baseline Mg++ 0.67 + 0.03mmol/l) [ lmmol/1 is 
equal to 24mg/ l]. The animals were intubated and ventilated. An infusion of 
bupivacaine was commenced and at the onset of seizure activity and 
cardiovascular collapse ( as determined by pre-defined criteria) the total 
dose and ·plasma concentration of bupivacaine was noted. All animals 
maintained a sinus rhythm until at least 6mg/ kg bupivacaine had been 
delivered. The bupivacaine infusion resulted in PR and QRS interval 
prolongation in both groups. PR interval prolongation was not statistically 
different between groups at 6mg/ kg. Widening of the QRS complex in the 
control group occurred after the infusion of 3mg/ kg bupivacaine but in 
the magnesium pretreated group the QRS prolongation only occurred after 
6mg/kg had . been infused. By then the Mg++ group also had statistically 
evident QRS prolongation but the control group had lengthened 
significantly more than the Mg++ group. This study showed that Mg++ did 
not increase the convulsant threshold but was effective in preventing the 
cardiac dysrhythmias associated with bupivacaine toxicity in dogs. However 
it was unable to help explain the mechanism of bupivacaine cardiac 
toxicity and seems to be the only trial looking at the role of magnesium in 
the prevention of the cardiac effects of bupivacaine. The model is however 
not the one most applicable to the clinical scenario of bupivacaine toxicity. 
75 
It would be of greater clinical relevance to test whether magnesium would 
be useful in treating the established cardiac effects of bupivacaine. 
4.2~(3.2) ROLE OF HYPOXIA/ ACIDOSIS 
Albright's editorial [17] followed 6 anecdotal cases -to his knowledge- of 
sudden cardiovascular collapse associated with rapid intravenous injection 
of bupivacaine. All .the cases occurred in operating rooms under the direct 
supervision of anaesthesiologists following negative aspiration tests. 
Sudden cardiovascular collapse (ventricular fibrillation or ventricular 
tachycardia, asystole, or complete heart block with P waves only) occurred 
almost immediately after rapid injection of the local anaesthetic agent, so 
that he felt that antecedent hypoxia probably was not an aetiologic factor. 
Work by both Mets' (21] and Nancarrow (79], in rats and sheep respectively 
demonstrated that respiratory depression occurs before the serious cardiac 
affects with bupivacaine toxicity. 
Mallampati reported (10] a case of successful resuscitation which they 
attributed to the early aggressive institution of cardio-respiratory support. 
At the time they concluded that there was mounting clinical evidence that 
prevention of hypoxia was associated with a good outcome. 
Kotelko et al (13] studied tracheostomised ewes which had rapid treatment 
of seizures and never became hypoxic or hyperkalaemic. All of the animals 
receiving standard epidural doses of bupivacaine developed serious 
arrhythmias. However their mortality rate was very low and Kotelko 
postulated that, considering other evidence, hypoxia and acidosis potentiate 
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the cardiotoxicity of bupivacaine and that under conditions of hypoxia and 
acidosis the incidence of fatal arrhythmias may have been higher. 
De Jong [8] also studied cats and found that adequately ventilated and 
oxygenated cats were able to survive twice the convulsant dose. If 
hypotension was also corrected with ephedrine they could survive 3 times 
the convulsant dose. They found that regular nodal and ventricular 
arrhythmias appeared with bupivacaine and etidocaine but not with 
lignocaine. They also found that the QRS complex began to widen and 
increase in amplitude within 1 mg/kg of infusion. All bupivacaine treated 
animals had arrhythmias by the time that seizures started. They showed 
that, within limits, in well ventilated and oxygenated cats - that the support 
of ventilation and the correction of hypotension with ephedrine- were 
vital elements in resuscitating animals given cardiotoxic doses of 
bupivacaine. 
Chadwicks' study [51] involved 20 cats which were anaesthetised, paralysed 
with pancuronium and ventilated to avoid the possible effect of acidosis, 
hypoxia and hypercarbia. They used EEG seizure activity as a CNS endpoint 
and a MAP of 1 OmmHg as cardiovascular endpoint and used infusion rates of 
4mg/ kg/ min for bupivacaine and 16mg/ kg/ min for lignocaine and 
recorded the times to each endpoint. 
They found that the, onset time of electrical seizure activity was virtually 
identical in both groups. Despite earlier onset of electrocardiographic 
changes in the bupivacaine group, mean arterial pressure was greater and 
remained so for longer than in the lignocaine group. They established that 
the CVS/ CNS toxicity ratio was 4.0 with lignocaine and 4.8 with bupivacaine. 
Despite very high lignocaine plasma levels all animals were resuscitatable; 
two of the bupivacaine group were not resuscitatable although this was not 
statistically significant. 
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The use of pancuronium in this study may have influenced the results in 
the light of more recent evidence implicating the central activation of the 
sympathetic nervous system in bupivacaine cardiotoxicity. The value 
anached to the CVS/CNS toxicity ratios needs to be interpreted in the light 
of the assumptions made at the design stage when they equated an infusion 
rate of 4mg/kg and 16mg/kg per minute to be equal for bupivacain_e and 
lignocaine respectively. Presumably this was based on the commonly 
quoted clinical potency equivalents of 0.5% bupivacaine and 2% lignocaine. 
Heavner [ 42] looked at the effect of hypoxia in intact pigs and demonstrated 
that ventilated pigs with fractional inspired oxygen content (Fi-Oz} of 0.1 
and 0.1 S showed a decreased threshold for the CNS and cardiovascular 
toxicity of bupivacaine. In addition Heavner observed an initial increase in 
heart rate in the Fi-Oz 0.3 group and noted an increased baseline in the 
other 2 groups. This is interesting as hypoxia has been shown to be a potent 
stimulant of the sympathetic nervous system and bupivacaine has been 
postulated to have similar actions. Therefore the increase in the 0.3 group 
could be hidden in the other groups who may already have had sympathetic 
stimulation via a hypoxic stimulus. 
Others [93] studied sheep rendered acidotic and hypoxaemic and gave a 
similar dose to those used by Kotelko [13]. They found the incidence of 
electrocardiographic changes similar in both studies but whereas only one 
bupivacaine animal died in the first study, 100% of bupivacaine treated 
animals died after the higher dose in the this study. 
78 
4.2.(3.3) ROLE OF PREGNANCY 
There was concern about the high number of obstetric cases of 
bupivacaine cardiotoxicity occurring in the literature[ 48] . Some studies 
had suggested that pregnant animals may be more susceptible to 
bupivacaine toxicity than to other local anaesthetic agents. 
Morishima et al [14] compared the toxicity of lignocaine and bupivacaine in 
nonpregnant and pregnant sheep. They demonstrated that during 
bupivacaine infusion convulsions were associated with hypertension and 
tachycardia. The .dosage given was correlated with the plasma levels by 
means of a ratio. Significantly higher dosage and blood concentration 
ratios were noted in the lignocaine group. 
Similar doses of bupivacaine [14] were needed to produce convulsions in 
pregnant and nonpregnant animals. However a lower dose of bupivacaine 
was necessary to produce cardiotoxicity in the pregnant animals. Although 
a small study it seemed to indicate that pregnancy was a predisposing factor 
to bupivacaine cardiotoxicity. 
Santos et al [48] looked at the comparative systemic toxicity of ropivacaine 
and bupivacaine in pregnant and nonpregnant ewes. They found that the 
onset of bupivacaine's toxic manifestations occurred in the following 
sequence: convulsions, hypotension, apnoea, and circulatory collapse. 
There were no significant differences between nonpregnant and pregnant 
animals in the doses or serum concentrations required to elicit toxic 
manifestations. In nonpregnant animals, similar doses and serum 
concentrations of ropivacaine and bupivacaine were associated with the 
onset of convulsions and circulatory collapse. In pregnant ewes, greater 
doses of ropivacaine as compared bupivacaine were required to produce 
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convulsions and circulatory collapse. The proportion of animals 
manifesting a malignant arrhythmia as the terminal event was similar 
amongst all groups. 
Moller and Covino [84] exposed rabbits to 4 days of progesterone before 
examining the effects of bupivacaine and ropivacaine on the then isolated 
hearts and found the progesterone pre-treated animals were more sensitive 
to the effects of bupivacaine. This was not present in the hearts exposed to 
ropivacaine. They speculated as to whether the effects seen were on the 
basis of the ropivacaine being a single enantiomer or whether it was the 
different side chains of the 2 drugs that accounted for the difference. A 
further unanswered question is whether progesterone influences drugs 
binding to the sodium channel in excitable membranes? 
In summary the effect of pregnancy on bupivacaine toxicity is still 
undecided but the hormonal changes, and progesterone in particular may 
potentiate the cardiotoxic effects. 
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4.3 SUMMARY OF PROPOSED CARDIAC 
ACTION OF BUPIV ACAINE 
The cardiac effects of toxic doses of bupivacaine appear to be threefold: 
* Pronounced negative chronotropism and inotropism 
* Cardiac conduction disturbances -Sodium Channel 
-Potassium Channel 
-Calcium Channel 
*Central stimulation of sympathetic nervous system 
Depression of cardiac conduction via sodium channel blockade appears to 
be one of the primary mechanisms of bupivacaine's cardiac toxicity. 
However there would appear to be evidence that other ion channels may be 
involved and that the onset and offset may be not only activity-dependent 
but also different in character. Blockade of sodium channels develops 
during the upstroke and plateau of the action potential and dissipates 
during the diastolic interval between beats. Thus both changes in heart 
rate and in transmembrane diastolic potential, as well as any manuoever 
that alters the duration of the action potential plateau, may alter drug 
action [3]. 
The contribution of potassium channels seems to account for the increased 
duration of the action potential and accounts for the effect of specific 
potassium channel blockers in attenuating the effects of bupivacaine. In 
addition, the calcium channels seem implicated in some of the activity 
during the lengthened action potential duration and also once profound 
sodium channel blockade has seriously undermined the sodium channels' 
role in myocardial cellular depolarization. 
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s. RECOMMENDED TREATMENT 
s.1 LIGNOCAINE 
Llgnocaine is a class I anti-arrhythmic drug and is useful for the treatment 
of ventricular arrhythmias. Llgnocaine has been suggested as a treatment 
for the cardiac toxicity of bupivacaine, apart from a postulate based on the 
modulated receptor hypothesis there would appear to be little evidence for 
this indication. 
Although lignocaine has been used to treat ventricular arrhythmias 
induced by bupivacaine [46,67], this is contradictory to many other 
laboratory studies, including work from our laboratory [21], showing 
additive effects. 
De Jong and Davis [9] suggested that lignocaine could be used to treat the 
ventricular arrhythmias of bupivacaine toxicity. They performed a study 
in 34 cats given double the convulsant dose of bupivacaine followed by 
diazepam to stop convulsions. Six of these cats had persistent arrhythmias 
( only one ventricular tachycardia) which were successfully converted by a 
bolus dose of lignocaine. 
Another group [124] reportedly compared the ability of bretylium and 
lignocaine to stop pacing induced ventricular arrhythmias following 
cardiotoxic doses of bupivacaine to "open chest" dogs. In contrast to de Jong 
and Davis' study, they found that lignocaine enhanced the cardiotoxic 
effects of bupivacaine by reducing the threshold for ventricular 
tachycardia. Bretyllium raised the threshold and reversed established 
bupivacaine induced cardiovascular dysfunction. 
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The cardiac and respiratory toxicity of lignocaine and bupivacaine have 
been shown to be additive in rats by researchers at our institution [21]. 
The modulated receptor hypothesis depends on the dissociation constants 
for bupivacaine and lignocaine being relatively long and short, 
respectively. Suggestions that the lignocaine would competitively 
antagonise the bupivacaine do not allow for lignocaine's dissociation 
constant being so short that bupivacaine would rapidly return to the 
receptor and bind for a relatively protracted time. 
De la Coussaye et al [26] felt that since the main electrophysiological 
disturbance induced by bupivacaine was a potent inhibition of the fast 
inward current, resulting in a slowing of ventricular conduction 
velocities- which are well known to cause reentry phenomenon and hence 
ventricular arrhythmias- it was illogical to try and treat cardiotoxicity with 
another antiarrhythmic drug, such as lignocaine. 
A very recent paper by Fujita and co-workers [90] studied the infusion of 
lignocaine (1 %), bupivacaine (0.25%) or lignocaine (1 %) and bupivacaine 
(0.25%) mixture when infused into the anterior descending artery of pig 
hearts. The bupivacaine depressed the ventricular wall function 
significantly more than the lignocaine or the combination. However the 
mixture of lignocaine when infused with the bupivacaine raised the 
threshold for ventricular fibrillation as compared to the bupivacaine 
group. Whilst this is good evidence for raising the threshold for 
ventricular fibrillation it does not equate to being able to use it clinically to 
treat established toxicity. 
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s.2 ADRENALINE 
The initial assumption was that adrenaline was a first line drug for the 
treatment of bupivacaine cardiotoxicity. However Heavner (33] in a letter 
questioned the wisdom of this suggestion as their unpublished study on 
treatment in rats showed that aggressive use of adrenaline to treat 
bupivacaine toxicity resulted in marked hypertension and dangerous and 
often terminal ventricular dysrhythmias. In · addition, Feldman (32] 
concluded that the use of adrenaline to treat cardiovascular collapse 
following bupivacaine overdose was controversial and that vasopressor 
drugs with less direct cardiac effects may be more beneficial. 
Several reports of bupivacaine toxicity resistant seemingly resistant to 
adrenaline had caused some concern (69] and Butterworths group 
speculated that it was bupivacaine's interference in beta-receptor cAMP 
production that could explain this resistance. Butterworth et al (69] showed 
that bupivacaine inhibits cAMP production in an equipotent fashion 
compared with ropivacaine and mepivacaine. This inhibition of 
catecholamine induced cAMP production is early in the production 
pathway (33]. In a further study they showed that bupivacaine displaced 
beta-adrenergic receptor ligands from the receptor at concentrations 
associated with cardiovascular toxicity. However there seems to be some 
debate about evidence for the competitive nature of these interactions. The 
initial assumption was that adrenaline was a first line drug for the 
treatment of bupivacaine cardiotoxicity. However if the effect is not 
competitive then adrenaline may not be the ideal agent. 
Moore, Crawford and Scurlock (7 4] suggested that the addition of adrenaline 
might prevent or treat the myocardial depression caused by bupivacaine. 
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However this could not be confirmed in animals rendered hypoxic and 
acidotic and given bupivacaine both with and without adrenaline. 
Kambam and co-workers [91] studied the addition of adrenaline and 
phenylephrine to bupivacaine. In a rather crude experiment with rats 
they were able to demonstrate that adrenaline and phenylephrine 
increased the incidence of death from toxicity from 20% to 90% in animals 
given 1:200 000 adrenaline or phenylephrine together with a standard dose 
of bupivacaine. The same dose of the vasopressors had no mortality at all 
when given by itself. 
The recent review by Kerin and Somberg on proarrhythmia [96] produces 
several good reasons why adrenaline may not be the ideal agent to use 
concurrently with bupivacaine. The sodium channel blockers create the 
conditions of disequilibrium between conduction and refractoriness at 
ventricular level which allow for reentry to occur. Beta-adrenergic 
blockers have been shown to be protective against the development of 
these ventricular arrhythmias. In addition local release of catecholamines 
by various proarrhythmic agents is postulated to be the cause of their 
proarrhythmic properties and the use of beta-blockers attenuates this 
effect[96]. 
5.3 NORADRENALINE 
A case report [16] described the use of noradrenaline to correct the 
haemodynamic consequences of bupivacaine. In addition Wheeler [73] 
demonstrated that "sinus exit block" induced by toxic levels of bupivacaine 
could be reversed by noradrenaline. 
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5.4 BETA-BLOCKERS 
A case report [ 44] of a successful resuscitation in a patient receiving 
digoxin and a beta-blocker initiated speculation that the combination 
allowed easier resuscitation. Others believed that the combination lowered 
the threshold for toxicity and a study in animals [52] seemed to support this. 
5.5 BENZODIAZEPINES 
Numerous studies support the use of benzodiazepines to attenuate the 
cardiotoxic actions of bupivacaine [31,53,54,]. Intracerebroventricular 
instillation of benzodiazepines has been shown to potentiate the activity of 
GABA-ergic neurones [31] and suppress bupivacaine induced hypertension 
and arrhythmias . 
. Bernard's study [53] is cause for some concern with regard to the 
benzodiazepines' effect in combination with bupivacaine. Animals 
pretreated with diazepam showed increased thresholds for arrhythmias but 
not cardiovascular collapse and they were then more difficult to 
resuscitate. 
5.6 ATROPINE 
Several studies [34,35,52] have shown that atropine has no effect on 
bupivacaine toxicity. 
5.7 BRETYLIUM 
A group [124] led by Kasten compared the ability of bretylium against that 
of lignocaine to stop pacing induced ventricular arrhythmias following 
cardiotoxic doses of bupivacaine to "open chest" dogs. In contrast to de Jong 
and Davis' study they found that lignocaine enhanced the cardiotoxic 
effects of bupivacaine by reducing the threshold for ventricular 
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tachycardia. Bretylium raised the threshold and reversed established 
bupivacaine induced cardiovascular dysfunction. 
5.8 CALCIUM ANTAGONISTS 
Despite concern and evidence [87] about the potentiating effect of calcium 
antagonists on bupivacaine cardiotoxicity, a group [27] have shown that a 
specific dose (200ug/kg) of nimodipine offered some protection. The use of 
calcium antagonists as treatment cannot be supported with current 
evidence. 
5.9 CLONIDINE AND DOBUTAMINE 
Clonidine is known to potentiate the sensory and motor block of 
bupivacaine and is used clinically in the epidural space. Animal studies 
have shown raised thresholds for CNS and cardiotoxicity with clonidine 
pretreatment. The mechanism is not understood, but possible explanations 
include the slowing of heart rate by clonidine which is thought to decrease 
the cardiotoxic effect of bupivacaine (modulated receptor hypothesis). 
The second possible mechanism is a central action at alpha-2 receptors 
which have been shown to decrease sympathetic outflow from the locus 
coeruleus [28]. Clonidine has been shown to shorten the His-Purkinje and 
QRS duration. de La Coussaye [26] demonstrated that clonidine reversed the 
bupivacaine induced increases in QRS duration and PR interval in dogs 
although it exaggerated the bupivacaine induced bradycardia. The 
combination of dobutamine was a further improvement as it showed the 
same positive electrophysiologic effects with a maintained heart rate and 
improved ventricular contractility. 
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s.10 HEXAMETHONIUM 
Although the ganglion blocker, hexamethonium, has been shown to raise 
· the threshold for toxicity [31,35] it has not been shown to be effective once 
toxicity has been established. Its use as treatment for established toxicity 
cannot be recommended. 
s.11 PREVENTION OF HYPOXIA/ ACIDOSIS 
This is well established and is reviewed under this heading in the animal 
evidence section earlier. 
s.12 PACEMAKER 
Although there are no case reports describing the use of pacemakers for 
the management of bupivacaine cardiac toxicity, it is certainly an option to 
be entertained as the toxicity of a given serum concentration perfused 
through the intact heart seems to be dominated by conduction disturbance. 
Pitkanen's study [110] looked at isolated, perfused rabbit hearts and 
compared the ability of the hearts to be paced at atrial and ventricular 
levels with differing concentrations of lignocaine, bupivacaine and 
ropivacaine. Half of the hearts could not be atrially paced at 6 
microgram/ ml bupivacaine and 13 microgram/ml ropivacaine. All the 
ropivacaine hearts (at 13microgam/ml) could be paced in the ventricle 
and only one of six at 13 microgram/ ml bupivacaine. Following washout of 
the local anaesthetics all hearts could be paced at baseline voltages. This 
finding may indicate that the use of an external or internal pacemaker 
during resuscitation from local anaesthetic overdose may be useful. 
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6. MAGNESIUM 
6.1 MAGNESIUM METABOLISM 
Magnesium is the 4th most common cation in the body. Total body stores 
average lOOOmmol and the normal serum range is considered 0.7-1.25 
mmoVl. Approximately 50 % is contained in bone and 20-30% in skeletal 
muscle. The heart also has a high concentration of magnesium. Only 1 % of 
this magnesium is in the extracellular compartment. Extracellular 
magnesium is 55% unbound and ionised, 33% is bound to proteins and the 
remaining 12% is complexed to anions. 
Magnesium's physiological role is complex. Magnesium has multiple sites of 
action in basic cellular processes and is a metabollic cofactor in hundreds 
of enzymatic processes, especially those involved in energy metabolism. 
Magnesium is required for protein and nucleic acid synthesis and for 
several mitochondrial processes. Effects of magnesium on calcium mediated 
systems and the sodium-potassium-ATPase may be critical in explaining 
some of the cardiac actions of magnesium. Magnesium's action on calcium 
within cells includes: 
-Inhibition of sarcolemmal calcium flux 
-Competition with calcium for binding sites on actin 
-Modulation of the cAMP system. 
In addition magnesium is involved in ion transport systems, especially the 
Na-K-ATPase system where magnesium serves as a cofactor in this 
important membrane enzyme system and thereby influences the transport 
of sodium and potassium across cell membranes. 
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6.2 CELLULAR BASIS FOR THE 
E·LECTRICAL ACTIONS OF 
MAGNESIUM 
Several different potassium channels exist within cardiac cells. 
Intracellular magnesium promotes inward rectification of potassium 
through some of the potassium channels including the acetylcholine 
sensitive potassium channels[l 13]. These effects on the potassium currents 
increase intracellular potassium and prolong the action potential. 
Intracellular magnesium also appears to affect the delayed rectifier 
potassium channel that is responsible for membrane repolarization after 
an action potential. 
Magnesium has long been recognised as a physiological calcium channel 
blocking agent. Increased intracellular magnesium inhibits calcium entry 
through the dihydropyridine-sensitive sarcolemmal channels ( so called 
"slow channels") [113]. The effects of magnesium on the · calcium 
channel are to shorten the action potential duration. The 
physiological significance of these effects is uncertain but the potential 
exists for magnesium to control calcium currents across the membrane. 
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6.3 EFFECT OF MAGNESIUM ON THE 
HEART 
Mg++ has a long history as an anti-arrhythmic, especially for paroxysmal 
atrial tachycardia, atrial fibrillation, ventricular extrasystoles, and 
prolonged QT interval, and is also the treatment of choice for Torsade de 
Pointes. 
McLean [72], in a review on the therapeutic uses of magnesium, was of the 
opinion that " given its lack of serious lasting toxicity that consideration 
. should be given · to adding magnesium to any therapeutic arsenal for 
supraventricular and ventricular arrhythmias". 
Several studies have shown a negative chronotropic effect on the heart 
[113]. Neither atropine or propanolol alters this effect suggesting that the 
effect of magnesium on the sinus node is independent of the autonomic 
nervous system. In humans magnesium infusions have predominantly 
shown no significant change in heart rate but isolated case reports have 
described magnesium induced bradycardia . . There are reports[l 13] of an 
increased sinoatrial conduction time in normal persons given magnesium 
sulphate. A number of studies have reported AH interval prolongation, 
although others [113] found no clear prolongation but concluded that the 
effect may well be dose dependent. In extreme hypermagnesaemia QRS 
widening does occur. Intravenous magnesium does seem to increase the 
effective, functional and relative refractory periods of the AV node. 
Bectrophysiologic studies [72] have demonstrated that a magnesium 
infusion prolongs the PR interval in normal hearts. This is then followed 
by increased sinoatrial conduction time, an increased atrioventricular 
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nodal refractory period and no effect on atrial or ventricular 
refractoriness or conduction. 
The relationship between magnesium and QT interval is of particular 
interest. There is evidence for mild prolongation of the QT interval in dogs 
fed a magnesium deficient diet, although the possibility of other electrolyte 
abnormalities is present. Animal studies could show, in the setting of 
hypocalcaemia, that low magnesium causes prolongation of the action 
potential duration and the QT interval. Clinical support for isolated 
hypomagnesaemia causing increased QT · interval or for exogenous 
magnesium decreasing QT interval is scant. Despite Torsade de Pointes being 
predisposed to by prolongation of the QT interval, and magnesium being 
uniquely successful in its treatment, there remains no evidence that 
magnesium normalises the QT interval even after abolishing the 
arrhythmia [113]. 
Rowlands [99] in his book on ECG interpretation concludes that 
hypermagnesaemia induces ECG changes similar to hyperkalaemia and 
these are manifest as prolongation of the PR interval and widening of the 
QRS complexes. Others [72] have suggested that cellular excitability might 
increase with magnesium deficiency and this has led to some speculation as 
to whether magnesium would therefore be of much use as an anti-
arrhythmic in the face of normal magnesium levels. Further work [72] 
looked at thresholds for ventricular premature beats and fibrillation in dog 
hearts. They demonstrated a significant increase in threshold required to 
produce either premature ventricular contractions or ventricular 
fibrillation after magnesium chloride had been infused. Although they 
failed to record serum magnesium levels there was no reason to suspect that 
this group of healthy dogs had a deficiency of magnesium. They felt that 
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they were observing a physiologic effect of magnesium which they 
postulated to be based on modulation of transmembrane ion fluxes. 
Although magnesium is now accepted therapy for Torsade de Pointes, its 
role in the more commonly seen monomorphic ventricular tachycardias is 
not as clear. A single study [113] in humans found that 7 of eleven patients 
with haemodynamically stable monomorphic ventricular tachycardia 
converted to a supraventricular rhythm within 10 minutes after starting 
an infusion of 2 grams magnesium sulphate over 1 minute. The only 
reported side effect was that all patients experienced a warm flushing 
sensation. 
Two electrophysiologic studies [72] seemed to suggest that the greatest 
effect of magnesium infusion is on the nodal conducting tissue rather than 
on atrial or ventricular myocardium. This property may explain why 
magnesium has such good properties for blocking or slowing re-entrant 
circuits at the level of the node. In addition magnesium may exert its effect 
in terminating supraventricular arrhythmias through the same 
mechanism. 
Re-entrant circuits may play a role in the genesis of some ventricular and 
supraventricular arrhythmias. Automaticity changes may also contribute 
to both arrhythmia development and treatment. Magnesium's effect on 
decreasing ventricular excitability and a similar effect in the atria may 
explain its role in multifocal atrial tachycardia [72]. 
Other work [72] demonstrated a raised arrhythmia threshold in magnesium 
pre-treated dogs using an ischaemic canine myocardium model. 
93 
Magnesium therapy has been shown by Iseri et al [109] to be effective for 
ventricular arrhythmias intractable to either potassium replacement (if 
· hypokalaemic ) or the antiarrhythmics lignocaine or bretylium, even with 
normal serum magnesium levels. 
· A study by Viskin [119] compared the use of magnesium against adenosine 
for the treatment of supraventricular arrhythmias. Although less 
successful than adenosine, the electrophysiological measurements 
suggested that magnesium's mechanism of action was via conduction 
suppression in accessory pathways as well as in atrioventricular nodal 
tissue. 
In 1990 Solomon et al [11] showed that magnesium sulphate, when given to 
establish therapeutic concentrations prior to bupivacaine infusion, raised 
the threshold for the initiation of the cardiac toxicity. 
Recently Akazawa et al [SO] looked at the safety of boluses of magnesium 
under sevoflurane anaesthesia. They looked at the effects of 3 different 
doses of magnesium in both sinus rhythm and atrial pacing. The boluses of 
magnesium(30, 60 and 90mg/kg) significantly increased serum magnesium 
concentrations and significantly prolonged A-V nodal conduction time 
during sinus rhythm, intra-atrial and A-V nodal conduction time during 
atrial pacing and total ventricular conduction time at doses greater than 30 
mg/kg. His-Purkinje conduction time was increased at doses greater than 
60 mg/kg. RR and PR intervals and QRS duration were increased at doses 
greater than 30 mg/kg during both sinus rhythm and atrial pacing. Qfc 
interval remained unchanged during sinus rhythm. Their conclusion was 
that magnesium is safe during sevoflurane anaesthesia {up to 1.0 MAC), 
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even in high doses and that it may be used if indicated for cardiac 
arrhythmias and hypertension during sevoflurane anaesthesia. 
Magnesium has been shown to reduce conduction velocity of cardiac cells 
via a decrease in maximum upstroke velocity by blocking the sodium 
channel, although relation between upstroke velocity and conduction 
velocity may not be as direct as previously thought. Because Purkinje 
figures and ventricular muscle have almost the same ionic mechanisms for 
development of action potential, with conduction velocities dependent on 
the rate of rise of depolarization carried by the fast inward sodium current, 
significant prolongation of His-Purkinje and ventricular conduction time 
during both sinus rhythm and atrial pacing may explained by the sodium 
current blocking action of magnesium[SO]. 
QJ interval reflects the average action potential duration of ventricular 
muscle and is determined mainly by the balance between outward 
potassium and inward calcium permeability during ventricular 
repolarization. Because QTc interval remained unchanged, significant 
prolongation of QT interval during sinus rhythm can be attributed to dose 
related decrease in heart rate [SO]. 
More recent work by Nakaigawa and Akazawa (97] looked at the effects of 
60, 90 and 120 mg/ kg doses of magnesium sulphate on the cardiovascular 
system and myocardial metabolism. They used 9 mongrel dogs anaesthetised 
with pentobarbitone and fentanyl. They found that all 3 doses produced 
dose dependent decreases in systolic and mean blood pressure, heart rate, 
left ventricular dP/dt max. Stroke volume was increased and systemic 
vascular resistance decreased which they speculated may account for the 
unchanged cardiac output. The decreased afterload allowing the decreased 
contractility to be compensated for and hence preserved the pump function 
of the heart. The ECG changes were a significant increase in QRS duration 
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and corrected QTc interval but this was dose independent. ST segment, P 
wave and T wave configuration was unchanged at all doses. A dose 
dependent increase in sinus cycle length, PQ and QT intervals was seen with 
the magnesium. A possible shortcoming with this study is the use of the 
muscle relaxant, pancuronium which has nicotinic receptor inhibitory 
actions [34]. These inhibitory actions may interfere with the interpretation 
of some of the data; which they themselves attribute to possible sympathetic 
activation. The work was in agreement with others [97] who could show that 
magnesium may produce short-lived blockade of sympathetic ganglia and 
prevents the stimulating effects of potassium and acetylcholine on superior 
cervical ganglia in cats. 
Many studies looking at the effect of magnesium on the myocardium 
appeared to indicate that magnesium had little effect in changing the 
action potential of Purkinje fibres. However these studies [109] had mostly 
been carried out in Tyrodes solution which contains 7.14mg/ dl of free 
calcium. This amount is more than that present in normal plasma and may 
be enough to resist the action of magnesium. Chesnais et al [120] looked at 
the effect of reducing the calcium concentration- they observed that when 
the calcium concentration was reduced, magnesium shortened the plateau 
phase and the duration of the action potential. This was interpreted to 
indicate that magnesium had probably blocked the slow inward current 
carried by sodium ions. It is conceivable that magnesium had blocked the 
entrance of any calcium that was present. The pacemaker cells, in the SA 
and AV nodes, are largely dependent on calcium influx for phase O of the · 
action potential and other studies [109] have shown in giant squid axons 
that the calcium influx can be blocked by magnesium. 
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7. RATIONALE FOR I.V. 
MAGNESIUM AS THERAPY 
FOR BUPIV ACAINE 
CARDIOTOXICITY 
Multiple descriptions of the use of magnesium for the treatment of 
arrhythmias led to the successful use of magnesium in some particularly 
resistant cases of bupivacaine cardiotoxicity at Red Cross Children's 
Hospital. A literature search revealed previous work by Solomons [11] who 
showed an increase in arrhythmia threshold when a therapeutic plasma 
· 1evel of magnesium had been attained. 
The increased threshold seen by Solomons prompted a laboratory study to 
investigate the use of magnesium sulphate in established bupivacaine 
cardiotoxicity. Administration of bupivacaine to humans via the 
intravenous route was precluded by the known severe cardiotoxicity; thus 
an animal model was employed. 
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8. EXPERIMENTAL PROTOCOL 
The objective of this study was to attempt to mimic the cardiotoxicity as seen 
in the clinical setting and to test the hypothesis that magnesium sulphate 
would reverse established bupivacaine cardiotox:icity. Therefore it was 
proposed that readily visible (qualitative) changes on the ECG monitor, as 
used in theatre, should be studied. A literature review revealed other studies 
looking at measured parameters of the recorded ECG, and therefore this 
method was co~sidered. One previous study used the animals' baseline as the 
normal for the study and then defined deviations greater than 25% from 
the baseline as being abnormal. In this study we experienced a large 
variation in baseline parameters between rats, and there was concern 
about the ability to make accurate measurements from recorded ECG traces. 
Therefore a blinded, independent and senior cardiac anaesthetist was asked 
to make a qualitative interpretation of the rhythm strips. 
8.0 METHOD 
8.1 Ethical Approval: 
Ethical Committee approval was obtained for the use of 10 rats in a 
pilot study and 20 rats in a blinded, randomised and controlled study. 
8.2 Pilot Study: 
10 rats were used in a pilot study to determine the average 
bupivacaine infusion rates necessary to establish cardiotox:icity. 
These animals were also used to determine the effective therapeutic 
dose of magnesium sulphate. Initial ·doses used were 40mg/ kg, based 
on the loading doses used in humans to achieve therapeutic levels in 
eclampsia. These proved to produce profound hypotension that took 
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several minutes to reverse. A 20mg/kg dose of magnesium sulphate 
was found to reverse established bupivacaine toxicity as determined 
by ECG criteria, and to produce moderate hypotension that was short 
lived. 
· 8.3 Power analysis: 
Power analysis revealed that if we could successfully produce 
arrhythmias in 90% of rats studied, and if magnesium was successful 
in reversing the arrhythmias in at least 50% of the animals, then 
wee would need only twelve (12) animals in total to demonstrate the 
effect. As we were not certain that we would be able to induce 
toxicity in 90% of animals, we proposed to study twenty (20) rats (10 
in each group) . The control group would simply have bupivacaine 
infusion continued and would receive a saline placebo when the 
treatment group received the magnesium dose. 
8.4 Study Design: 
All animals studied were male Long-Evans rats weighting 250-350g, 
from the University of Cape Town colony. Following termination of 
the e"-'Periment rats were euthanased with a bolus dose of 
bupivacaine. 
Two rats were studied each day in the microsurgical laboratory. 
Rats were anaesthetised with 60mg/kg of intraperitoneal 
pentobarbitone. 
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Once adequate anaesthesia was established as measured by absence of 
response to snout stimulation they were placed supine on a cork 
board and the snouts fixed to the board using a rubber band. 
Endotracheal intubation was performed using a modified paediatric 
Macintosh laryngoscope and individually manufactured 
endotracheal tubes. 
Rats were then ventilated with air. A tidal volume of 15 ml/kg was 
utilised at a rate of 60 breaths per minute using a Harvard Apparatus 
Rodent Respirator. The ventilator settings remained unadjusted for 
the duration of the experiment so that the tight control of rat 
weights provided similar degrees of ventilation for the two groups. 
Two intravenous lines were placed in the opposite femoral veins 
using an operating microscope. One was primed with 0.5% isobaric 
bupivacaine [Macaine, Adcock-Ingram] and the other primed with 
either the magnesium sulphate in a concentration of 20mg/ ml or 
saline which would be given in an equivalent volume. 
An arterial line [24G Jelco] was placed in one femoral artery under 
direct vision using the operating microscope. This was connected to a 
primed and heparinised Deltran II Disposable Pressure transducer 
[Utah Medical Products]. 
A Siemens Sirecrust 961 Critical Care monitor was used to record the 
invasive blood pressure and a 3 lead ECG using 3 needle electrodes 
placed subcutaneously in the left and right axillae and over the 
lower margin of the left praecordium. Standard lead II was monitored 
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and recorded. A Siemens Siredoc 220 printer was used to record the 
monitor data at a paper speed of 25mm per second. 
Following the stimulation of preparation the animals were allowed a 
15 minute timed "stabilization period" before the eA'J)eriment . . 
Following stabilisation the bupivacaine infusion was commenced at 
4ml/hour and increased by 1 ml/hr every 4 minutes until cardiac 
toxicity was established by the following criteria: 
-ventricular arrhythmias or fibrillation 
-multifocal atrial arrhythmias 
-grossly visible prolongation of the QRS complex 
-any AV conduction worse than 1st degree block 
The prime outcome measures were the incidence of reversal of 
cardiac toxicity ( as defined above) seen as: 
-abolition of ventricular arrhythmias or ventricular 
fibrillation 
-abolition of multifocal atrial cardiac arrhythmia's 
-reversal of a prolonged QRS complex 
-improvement of any AV conduction block. 
Once toxicity was established the infusion rate of bupivacaine was 
maintained, an arterial blood sample of 2ml was obtained and the 
volume replaced by 2 ml of normal saline. The ECG was recorded and 
then the pre-randomised treatment (magnesium sulphate 20mg/kg 
or an equal volume of saline) given by a rapid bolus over 1-2 
seconds. ECG monitoring was maintained and any changes recorded. 
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Two minutes after the initial treatment, the infusion was terminated 
and if ECG features were still considered abnormal then a second dose 
of treatment or placebo given. 
Rats then remained under observation for a further 10 minutes and 
any changes were recorded. 
The ECG recordings and the time from _starting the bupivacaine 
infusion were presented in chronological order to a blinded 
observer( a senior cardiac anaesthetist) with the following 
information: 
-time of trace 
-baseline trace labeled 
-early toxicity labeled 
-established toxicity trace labeled 
-trace immediately post treatment 
-trace at two minutes post treatment 
-trace at three minutes post treatment 
-trace at four minutes post treatment 
-traces from any other times where noteworthy changes had 
occurred, were presented with the relevant time indicated. 
The blinded, independent observer had been given a copy of the 
protocol and was asked to comment in detail on the rate, rhythm, PR 
interval and QRS complex in each trace, and then to make a decision 







The mean weight of the male Long-Evans rats was 293g ± 16.4g. The was no 
significant difference between the groups. 
Arterial samples were taken from the 2nd rat studied each day and blood 
gases analysed. An incomplete sample(8 rather than 10) was due to 
technical difficulties obtaining enough blood from the rats at the end of 
the experiment. The quantity of blood required for analysis precluded us 
from taking specimens earlier in the experiment. Blood gas analysis was 
done to audit our ventilation (see appendix 1. ) and the results indicate that 
all the checked animals were adequately ventilated and oxygenated. Despite 
concerns regarding statistical analysis of such a small sample the analysis 
is included to demonstrate the lack of any differences. 
Four of nine rats in the magnesium group received a second dose of the 
treatment and five of the ten rats in the placebo group received a second 
dose. There is no significant difference in the volume of fluid that the two 
groups received. 
Groups were compared using Fisher's Exact test. 
Two samples of the ECG traces from one rat in each group are included as 
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RESULTS AT 4 MINUTES 
CONTROL 
No response 
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Students t-test (assuming unequal variances) 
p = 0.413 = NO SIGNIFICANf DIFFERENCE BETWEEN GROUPS 
Three rats (underlined) in the control group (Rats 4, 8 and 20) received far 
smaller total doses of bupivacaine than the rest of the rats. Two of these rats 
(4 and 20) were noted at the time to have "very early toxicity". Rat number 
4 was the only control rat which seemed to respond within 2 minutes to the 
saline placebo. By 4 minutes after initial treatment rats 8 and 20 were the 
only other two control rats which seemed to respond to placebo 
If these three rats as a group are compared to all the remaining rats then : 
the three rats in the control group which responded to placebo received a 
mean dose of bupivacaine of 5. 7mg ± 1.3mg[Mean ± SD] 
107 
The remaining 16 rats received a mean dose of bupivacaine of 15.7mg ± 
4.8mg 
When the doses of bupivacaine were compared using Student's t-test 
p = 0.003 = Highlv significant difference 
These results indicate that the responders in the control group were the 
rats receiving significantly less bupivacaine than the remaining rats as a 
group. This probably explains their early response to termination of the 
bupivacaine infusion. The results are still significant despite the apparent 
response of these three rats in the control group. It was decided not to 
exclude them from the statistical analysis as they would only serve to 
increase the significance of the results. 
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10. DISCUSSION 
Bupivacaine cardiotoxicity, as reviewed earlier, remains a serious 
complication when it occurs, and no effective treatment is known. 
The results of this study show that in intact rats magnesium produces a 
more rapid resolution of bupivacaine induced electrophysiological changes 
than placebo. The improvements are in rhythm and electrical conduction, 
although this is often at the expense of potentiating the bradycardic effects 
of bupivacaine toxicity. Whilst the bradycardia remains a problem it is 
. potentially more ·amenable to therapy than the changes in rhythm and 
conduction which magnesium sulphate reversed. The opportunity 
therefore exists to explore the possibility of combining magnesium with a 
positive chronotrophic agent such as dobutamine [26]. 
This study was performed in an intact animal model and this raises several 
questions about its significance. The use of animals is necessary in view of 
the severe consequences of the drug at toxic levels in humans. However 
there is concern about extrapolating this kind of data to humans, 
particularly in the light of concerns (as previously discussed by Van den 
Berg-personal communication) about the different roles and timing of ion 
channel opening in the rat myocardial action potential when compared to 
primates. A further compounding factor is that pentobarbitone suppresses 
the central nervous system including the sympathetic nervous system and 
has been considered to raise the threshold for bupivacaine cardiotoxicity. 
However it was used uniformly in this study, so that there was no bias 
between groups. Pentobarbitone has an action similar to thiopentone and 
other general anaesthetics which are often used concurrently with local 
anesthetic drugs. Unfortunately due to differences in preparation times for 
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each animal there may have been differences -in the state of anaesthesia of 
the animals. The single dose of intraperitoneal pentobarbitone seemed to 
provide adequate anaesthesia for the duration, and the only control was the 
timed period allowing animals to recover from the surgical stimulation. The 
table giving the bupivacaine doses provides some idea of differences 
between the groups as the step-wise increases in infusion rate were all 
timed. An additional concern is the use of surface ECG recordings in an 
anempt to determine what the drug is doing to individual action potentials 
in different areas of the intact heart. Analysis of the surface ECG limits 
ones ability to make deductions and hypotheses about what is happening at 
a cellular level with regard to bupivacaine's toxicity and magnesium's 
therapeutic action. 
The mechanism of bupivacaine cardiac effects remains poorly understood 
but current knowledge seems to support the involvement of several ion 
channels in the direct cardiac effects. Bupivacaine certainly decreases 
V max of the action potential. This effect is almost certainly mediated by 
blockade of the sodium channels responsible for phase O of the action 
potential. If the decrease in Vmax was an isolated effect then one would 
expect that the extent of depolarisation would be decreased, accompanied by 
a decrease in length of action potential plateau and duration. 
However evidence suggests that toxic doses of bupivacaine lengthen the 
action potential duration largely by prolonging the plateau duration. A 
study looking at the dose-response relationship between the action 
potential duration and bupivacaine concentrations in isolated hearts 
demonstrated that at low concentrations the action potential plateau's were 
shortened, suggesting a predominance of sodium channel blockade. At 
concentrations above SmM( 1.43ug/ml) [73] the action potential plateau 
110 
duration increased suggesting that either potassium or calcium channel 
block was now dominant. This is based on knowledge that lengthening of 
the action potential duration is always due to a mechanism independent of 
the cause of the decrease of Vmax (J Vandenberg-personal 
communication). 
Bupivacaine has however been shown to increase the action potential 
duration in frog and canine atrial wall muscle and also in canine 
ventricular septal wall. However the action potential duration has been 
shown to be decreased by bupivacaine [62] in canine and rabbit Purkinje 
fibres. Therefore it is possible that there may be regional differences in 
effect of bupivacaine on action potential duration and this may result in 
areas differing in excitability, i.e. dispersion, which in turn could 
precipitate re-entrant arrhythmias [3,62]. 
Wheeler's group [73] showed that, in the presence of bupivacaine, atrial 
activity conveyed to the AV node was conducted to the septum but did not 
produce excitation of the atrium. They were able to demonstrate "bizarre" 
localized blocks and conduction patterns within the AV node which 
predispose to re-entrant arrhythmias. Premature septal beats, were 
observed to arise from the AV node, with re-entry being the likely 
mechanism of the extra beats. Bupivacaine was shown to be 20 times more 
potent than lignocaine in depressing action potential(AP) properties in 
atrial cells. In septal cells the AP changes were more variable although the 
depression of V max was more pronounced with bupivacaine. Septa} cells 
also showed an action potential lengthening with bupivacaine. Ventricular 
muscle action potential lengthening occurred with bupivacaine and this 
also occurs with drugs such as quinidine which, like bupivacaine, also 
predispose to Torsade de Pointes. 
111 
The effect on the body-surface ECG of decreasing Vmax in the ventricular 
· muscle mass is to increase the QRS complex duration. The effect of 
increasing the duration of the action potential plateau and therefore the 
action potential duration is to increase the QT interval. An increase in QRS 
. complex duration accompanied by an increased QT interval are almost 
universal in studies looking at the electrophysiological changes seen in 
bupivacaine cardiotoxicity. Both these findings are well known to be 
associated with an increased risk of reentry and with resultant ventricular 
arrhythmia's, especially Torsade de Pointes, which has often been 
associated with bupivacaine cardiotoxicity. 
Evidence for the initiation of Torsade de Pointes seems to point to a 
significant contribution of reentrant phenomenon and also possibly 
independently to a role for QT prolongation. Torsade de Pointes tends to 
develop in association with antiarrhythmic drugs that block sodium 
channels and prolong the QT interval [89]. However not all sodium channel 
blockers predispose to reentrant phenomena. An index of degree of 
dispersion of the sodium channel blocking effect would seem more 
important. Evidence would support the notion that increased dispersion of 
repolarization is strongly correlated with the risk of development of 
Torsade de Pointes. This has recently been reviewed by Nattel [121] when 
considering pro-arrhythmia by sodium channel blockers. Drugs thought to 
induce Torsade de Pointes have been found to produce spatial and temporal 
APD heterogeneity in the ventricle which may predispose to induction of 
re-entry phenomena by early after depolarization's(EAD's). Facilitators of 
the long OJ syndrome predisposing to EAD's include bradycardia, 
hypokalaemia and hypomagnesaemia. Nattel also speculates that the drug 
induced EAD's upstroke is generated by the L-type calcium current- which 
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may explain the susceptibility to arrhythmias with hypomagnesaemia and 
may explain why magnesium is a useful therapeutic agent for EAD induced 
arrhythmias. Indeed there may be a specific population of deep 
subepicardial myocardial muscle cells with APD behaviour which 
resembles Purkinje Fibres [121] and which equally readily display EAD's in 
response to various drugs, predisposing to Torsade de Pointes. Further 
evidence of the role of EAD's comes from in-vivo work [121] showing that 
drug induced ( using a potassium channel blocker model predisposing to 
Torsade de Pointes) EAD's and/or ventricular arrhythmia's were 
suppressed by magnesium, diltiazem, beta-blockers and sodium channel 
blockers [121]. 
Electrolyte abnormalities, including hypokalaemia and hypomagnesaemia 
may prolong repolarization and precipitate ventricular arrhythmias [89]. 
The argument for reentrant cycles inducing Torsade de Pointes is not 
complete and several issues remain unresolved, although the observations 
that dispersion of repolarization and delayed activation of the ventricle are 
present in patients with the long QT syndrome provides further rationale 
for the implication of reentry in Torsade de Pointes[89]. 
De La Coussaye's epicardial mapping of reentrant pathways [25] during 
bupivacaine toxicity in isolated rabbit hearts provides good evidence for 
reentrance as an initiating factor in bupivacaine toxicity. 
The beneficial effect of magnesium in the treatment of Torsade de Pointes is 
not clear, but it is assumed that it is related to its ability to stabilise 
membrane potential, thereby reducing the excitability of the cell 
membrane [96]. Magnesium's effect in treatment of Torsade de Pointes 
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occurs despite it seeming to have no effect on the prolonged QT interval 
which is thought to predispose to the arrhythmia [113]. There is speculation 
that magnesium's calcium blocking properties may depress some forms of 
automaticity, such as triggered activity, which may underlie the genesis of 
Torsade de Pointes [89]. Indeed recent work [122] has attempted to quantify 
the role of EAD's, bradycardia potentiated AP lengthening_ and 
interventricular dispersion of AP lengthening . in acquired Torsade de 
Pointes; and the role of magnesium in the reversal of ventricular 
dispersion. Verduyn's group [122] demonstrated that in Torsade de Pointes 
susceptible dogs that interventricular APD dispersion correction by 
magnesium sulphate was accompanied by an inability to induce Torsade de 
Pointes. This was in contrast to no demonstrated change in intraventricular 
APD in either ventricle when they were studied separately. 
Magnesium has long been recognised as a physiological calcium channel 
blocking agent. Increased intracellular magnesium inhibits calcium entry 
through the dihydropyridine-sensitive sarcolemmal channels (so called 
"slow channels") [113]. The effects of magnesium on the calcium channel 
are to shorten the action potential duration. [113] The physiological 
significance of these effects is uncertain but the potential exists for 
magnesium to control calcium currents across the cell membrane. 
Bupivacaine induced lengthening of the action potential plateau produces 
QT interval prolongation. Reentry due to lengthening of the action 
potential, accompanied by prolonged QT interval, is widely accepted as 
playing a significant role in bupivacaine electrophysiological toxicity 
often leading to Torsade de Pointes. Magnesium has been shown to shorten 
the duration of the action potential plateau [113] . and this is a possible 
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explanation for the early correction of the electrophysiological changes 
seen in this study. 
Bupivacaine toxicity can be devastating when it occurs and this study, 
whilst not providing a cure, does offer some direction in terms of new 
forms of treatment. In addition it may open up new ways of approaching 
the mechanism of bupivacaine cardiotoxicity, as magnesium may be play a 
role at a cardiac level, in the central nervous system, or at both sites. 
Further studies are needed to elucidate the exact mechanism and site of 
action of magnesium sulphate in the setting of the complex cardiac 
electrophysiological abnormalities induced by bupivacaine. 
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Appendix 1. ARTERIAL BLOOD GASES 
Group pH p02 pC02 BE 
~ Control 7.47 17.8 4.0 -1.2 
~ Control 7.47 12.92 3.45 -3.8 
1L.. Magnesium 7.45 15.3 5.02 2.5 
li.a... Magnesium 7.48 15.18 3.95 -0.9 
13. Magnesium 7.49 14.28 3.94 -0.2 
14. Control 7.51 11.55 2.83 -5.1 
18. Magnesium 7.55 13.92 2.80 -3.5 
12, Control 7.55 14.77 3.32 -0.3 
CONTROLS MAGNESIUM 
JD2 14.26.± 2.7 14.67 ±0.67 
µX)2 3.4 ± 0.48 3.92 ± 0.9 
pH 7.5 j-0.03 7.495 :+- 0.041 
Base excess -2.6 :+ 2.23 -0.52 .+ 2.46 
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Appendix 2: Toxicity Criteria 
Controls 
Rat Toxicity Criteria 
1 sinus bradycardia 
3 Sinus bradycardia, 2nd degree AV block(Wenkebach), 







Sinus bradycardia with dropped beats, intraventricular 
conduction delay, AV block(possible mobitz II) 
Severe sinus bradycardia, 2nd degree AV block 
Sinus bradycardia, 2nd degree AV block progressing from 
type I to type II 
Sinus bradycardia, 2nd degree AV block( type I), slow 
ventricular rate 
Sinus bradycardia, 2nd degree(typell) AV block 
Sinus bradycardia, 1st degree AV block, intraventricular 
conduction delay 
19 Sinus bradycardia, 1st degree AV block, poor intraventricular 
conduction 
20 Regular rhythm, possible SVT with aberrant conduction 
Magnesium: 





sinus bradycardia, QRS widening and intraventricular 
conduction delay 
Sinus bradycardia, 1st degree AV block, wide QRS 
Sinus bradycardia, QRS widening, dropped beats 








Sinus bradycardia, 1st degree AV block, intraventricular 
conduction delay 
Sinus bradycardia, 1st degree AV block, intraventricular 
conduction delay 
Sinus bradycardia, 2nd degree AV block(typel) 
1st degree AV block, severe intraventricular conduction block 
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